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1 Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder and one of the most common
forms of dementia in elderly humans (50-70 % of all cases) [1]. In 1907 the german psychi-
atrist Alois Alzheimer published a case study about the 51 year-old woman Auguste Deter
in ”On an Unusual Illness of the Cerebral Cortex” (”Ueber eine eigenartige Erkrankung
der Hirnrinde”) [2]. In this article, he described cognitive and behavioral impairments
of the patient and related these deficits with postmortem identified neurofibrils, ”miliary
foci” (today: amyloid plaques), and a general atrophy of the brain. Today, considered clin-
ical symptoms are episodic memory deficits at an earlier stage, followed by an increasing
confusion and memory loss during disease progression. In the later stages psychological
and behavioral problems occur, such as hallucination, agitation, wandering, up to loss of
body function control in the latest stage [3].
The neuropathology of AD is characterized by a severe synapse and neuronal loss,
extracellular aggregated amyloid beta (Aβ) peptides (amyloid or senile plaques), and
intracellular neurofibrillary tangles, which consist of hyperphosphorylated tau protein (a
microtubule-associated transport protein). In Fig.1.1.a, a representative image of the
typical look and distribution of plaques (brownish spots) and tangles (black tri-angled
shapes) within an AD brain tissue is shown. The hippocampus is the most affected
brain area by these neuropathological lesions, followed by cortical regions and others (e.g.
amygdala) [1, 4]. This gradual process is accompanied by a shrinkage of cerebral cortex
and an enlargement of ventricles (Fig.1.1.b) [3].
Depending on the disease onset, one can differentiate between two forms of AD. One of
those is an early-onset genetically-dominated form, whereas the other one is a so-called
sporadic or late-onset form. The early-onset (meaning disease onset before 60-65 years of
age) is caused by autosomal-dominant mutations in Aβ generation-related genes, why it
is also known as familial AD (FAD) [5]. While this form of AD is relatively rare (1 %) [1],
the sporadic AD forms the majority of all cases [6]. The greatest risk factor developing
AD is age, although genetic factors, e.g. mutation in APOE4 gene [6], or environmental
factors are thought to play a substantial role. Several epidemiological studies considered
also depression, traumatic head injury, lower education level, and risk factors associated
with heart disease and stroke such as cigarette smoking, obesity, high blood pressure and
high cholesterol as promotive factors [4].
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Figure 1.1: Histopathological hallmarks of AD
(a) Amyloid plaques (brownish spots) and neurofibrillary tangles (black triangled shapes) in a
AD brain tissue. (b) Schematic view of an atrophic AD brain compared to a healthy control.
Remarks are shrinking of cortex and enlargement of ventricles. Image (a) from [7] and (b)
from [3].
1.1.1 APP processing and amyloid beta generation
Amyloid plaques rise from the aggregation of a proteolytic cleavage product of the amy-
loid precursor protein (APP). APP is a single-pass transmembrane protein of cell plasma
membranes, containing a short cytoplasmic domain and a large extracellular domain.
Its actual function is unknown, although studies about protein functional domain map-
ping considered metal binding, protease inhibition, or neurotrophic and adhesion function
[8, 9]. Two different competitive degradation pathways for APP metabolism exist. At the
site of plasma membrane, APP is predominantly proteolysed by α-secretases. Processing
of APP by α-secretase competes with β-secretase, thus preventing the production of toxic
Aβ peptides and therefore called the non-amyloidogenic cascade. Here, the proteolytic
processing leads to the production of sAPPα protein and CTFα peptides (C83), as inter-
mediates. CTFα in turn is further cleaved by γ-secretase. End products of this pathway
are small non-toxic protein fragments p3 and APP intracellular domain (AICD) that do
not aggregate (Fig.1.2).
Internalization of plasma membrane-bound APP into early endosomes activates the
amyloidogenic pathway of APP cleavage. In early endosomes, APP is proteolytically
processed by β-secretase or BACE1 (β-site APP-cleaving enzyme-1) leading to a soluble
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form of APP (sAPPβ) and a membrane-fixed CTFβ (C99). This fragment is now cleaved
by presenilin, the catalytic subunit of the multiprotein complex γ-secretase, releasing Aβ
monomers (length 36-43 amino acids) and an AICD fragment (Fig.1.2) [8, 10, 11].
Figure 1.2: APP processing
Non-amyloidogenic cascade: APP processing by α-secretase produces soluble APP-sα protein
and CTFα fragment. Amyloidogenic cascade: Cleavage of APP by β-secretase (BACE) results
in soluble APP-sβ protein and CTFβ fragment, which is then processed by γ-secretase to toxic
Amyloid-β petides. These are secreted into the extracellular space and form extracellular
amyloid plaques. Image from [10].
Most of the Aβ isoforms have a length of 40 or 42 amino acids with Aβ42 showing
the highest tendency to aggregate [12]. The aggregation is a kinetic process which starts
by dimerization of Aβ monomers, formation of meta-stable oligomers (lag or nucleation
phase) and protofibrils, and at last the extracellular deposition of insoluble, thermody-
namically stable fibrils (elongation phase) as so-called senile plaques (Fig.1.3) [8, 10, 13].
Figure 1.3: Kinetic model of Aβ polymerization
Formation of mature Aβ fibrils can be divided into two processes: Dimerization of mis-
folded Aβ monomers and formation of metastable oligomers as aggregation nuclei (nucleation
phase), followed by the thermodynamically-driven formation of stable mature fibrils (elonga-
tion phase). Illustration adapted from [14].
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1.1.2 Mouse models of AD
In FAD three different genes, APP, PSEN1, and PSEN2 (which both are genes for pre-
senilin protein), have been identified bearing autosomal mutations leading to a massive
overproduction of toxic amyloid beta peptides in these patients. All commonly used trans-
genic mouse models of AD overexpress mutated forms of either one or more genes found
in patients with FAD. In APP, more than 20 pathogenic mutations have been identified,
most of them caused by amino acid exchange, e.g. K670D/M671L (so-called swedish mu-
tation) or V717F (Indiana mutation). However, more than 130 mutations have been found
in PSEN1 or PSEN2 genes, causing the majority of FAD cases [1]. Expression of different
human APP mutations or PSEN1, alone or as double transgenic mouse strain, results in
different phenotypes (see table 1.1). For example, the intensity of plaque development
differs between 5 to 14-fold of endogenous amyloid beta expression, depending on the
mutation or the promotor used in the mouse model [15, 16, 17]. Additionally, some show
a higher pre-mature death rate and epileptic seizures, while others do not [1]. However,
most of all existing APP/Aβ overexpressing mice show AD-like pathologies as cognitive
impairment and amyloid deposition. Although apparent neuronal loss is not visible in all
strains, several mouse models exhibit neuritic injuries or synaptic dysfunction [18]. Table
1.1 lists the most common mouse models for AD and their AD-like pathologies.
Table 1.1: Expression of different APP mutations in AD mouse models and
related phenotypes
Aβ: Aβ pathology, NL: neuronal loss, SD: synaptic dysfunction, MD: memory deficits,
†: pre-mature death. Table adapted from [1]
Strain Gene Phenotype Reference
APP23 hAPP695swe Aβ, NL, MD, † [1, 18]
(K670D/M671L)
Tg2576 hAPPswe Aβ, MD, † [1]
PDAPP hAPPV717F Aβ, MD [1]
PS1 M146L hPSEN1M146L Aβ [1]
APPswe(K594N/M595L) hAPP695swe Aβ, SD, MD, † [17, 19]
/PSEN1dE9 and PSENdE9
5xFAD APPswe,F lorida,London/ Aβ, NL, SD, MD [18]
PS1(M146L,L286V)
3xTg APPswe/Tau/ Aβ, SD, MD [1, 18]
PS1M146L
1.2 Inflammatory processes in AD
The old dogma that the brain is isolated from the immune system was totally reversed
after growing evidence indicated that instead there is a complex connection between both,
essential for maintaining homeostasis and defense against pathogens [10, 20]. Beside the
classical neuropathological hallmarks such as amyloid plaques and neurofibrillary tangles,
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the presence of inflammatory response is characteristic for the AD brain. This includes
the localization of complement factors in AD brains, production of pro-inflammatory
cytokines or MHC class II molecules by microglia, and a general activation of microglial
cells and astrocytes [21, 22]. Furthermore, long-term consuments of some non-steroidal
anti-inflammatory drugs (NSAIDs) have a lower risk to develop AD [20, 23, 24]. Microglia
show on the one hand a promoting effect on neurodegeneration by releasing neurotoxic
factors, but on the other hand they can phagocytose Aβ, thus preventing accumulation of
extracellular deposits [10, 22, 25]. Although these are inconsistent findings, it obviously
strengthens the notion of an important role of the immune system in the development of
AD [20].
1.2.1 Immune cells of the CNS - microglia
Physiological function of microglial cells
More than 25 years ago, it was found that microglia in an AD brain could be stained
with the use of a major histocompatibility complex (MHC) class II antibody, indicating
microglial cells are part of the immune system and negating the theory of an immunopriv-
iliged status of the brain [26, 27, 28]. The term ”microglia” was coined by Rio-Hortega,
a student of Ramo´n y Cajal (nobel prize winner for physiology or medicine 1906), who
classified as the first microglial cells as a third cell population within the CNS [29]. Mi-
croglial cells derive from mesenchymal myeloid progenitor cells, that migrate into the
developing brain during embryogenesis, where they proliferate and develop into central
nervous system (CNS)-resident microglial cells [28]. In Fig.1.4, the hematopoietic lineage
of microglial precursors is depicted. Microglia originate from common myeloid progenitor
cells rather than neuroectodermal or neuroepithelial progenitor cells [30]. Microglial cells,
as mononuclear phagocytes of the CNS, are close related to adult tissue macrophages, such
as perivascular, meningeal, or choroid plexus macrophages (Fig.1.4). As the CNS-resident
macrophages, microglia are responsible for immune surveillance and debris removal dur-
ing homeostasis [31]. Under physiological conditions microglia survey the environment
for necrotic or apoptotic cells, pathogens, or debris of misfolded proteins and other cellu-
lar components. Encountering pathogens or other detrimental factors like Aβ peptides,
microglia can undergo a morphology change, from ramified to ameboid, and possess an
reactive phenotype [29].
Phagocytosis of amyloid β
In AD brains, microglia are found close to amyloid plaques [32, 33], where they present
a highly activated phenotype [34]. It has been demonstrated in in vitro and in vivo
studies that microglia show Aβ uptake [35, 36, 37], and that they express several Aβ
receptors, such as scavenger receptors CD36 and scavenger receptor A (SRA), recep-
tor for advanced-glycosylation end products (RAGE), as well as Aβ degrading enzymes
5
1 Introduction
(matrix metalloproteinase-9 (MMP9), insulin-degrading enzyme (IDE), and neprilysin
(NEP)), indicating a promoting effect in Aβ clearance [38]. Furthermore, increased mi-
croglia accumulation in some mouse [39, 40] or rat [41] models of AD reduces AD-like
pathology, whereas impaired microglial accumulation accelerates Aβ deposition [42, 43].
Additionally, it was shown that cultured microglial cells on AD brain section lead to an
accumulation on amyloid plaques [44].
Figure 1.4: Hematopoietic origin of microglial cells
Shown are hematopoietic cell lineages of lymphocytes, platelets, erythrocytes, granulocytes,
neutrophils, etc., and mononuclear phagocytes. CNS cells, such as neurons, oligodendrocytes,
and astrocytes derive from neuroectodermal progenitor cells. Microglia, macrophages, mono-
cytes, and DCs derive from common myeloid progenitor cells, although microglia originate
only from extra-embryonic yolk sac myeloid cells during development. Image from [30].
In contrast, complete ablation of microglia in a mouse model of AD did not influence
amyloid plaque progression [45], and several studies showed that microglia were unable
to degrade internalized Aβ peptides, and Aβ accumulates within the cells for days or
weeks [46, 47, 48]. Moreover, there is evidence that the ability of microglial Aβ clearance
depends on the inflammatory phenotype of these cells. Stimulation of BV-2 microglial cells
with pro-inflammatory cytokines results in a significantly decreased Aβ42 phagocytosis
rate [49]. A reduced Aβ uptake and decreased expression of SRA and CD36 by mouse
microglia after stimulation with TNF-α was also demonstrated [38]. The authors could
also show that microglia isolated from old APP/PS1 mice express higher levels of IL-
1β and TNF-α than young APP/PS1 mice, together with a decreased expression of Aβ
degrading enzymes and receptors [38]. It has been suggested, and is called ”frustrated
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phagocytosis” [34, 50, 51, 52], that the inability of microglia to degrade Aβ results in a pro-
inflammatory, highly reactive phenotype that eventually contributes to AD progression.
On the other hand, stimulation of microglial cells via Toll-like receptors (TLRs) 2, 4 or
its co-receptor CD14, and TLR9 enhances their ability to internalize Aβ [34, 53]. TLRs
are pattern recognition receptors (PRRs), that basically recognize pathogen-associated
molecular patterns, e.g. lipopolysaccharides (LPS) found on bacterial cell surfaces. Cul-
tured microglial cells lacking TLR2, TLR4, or CD14 exhibit a reduced pro-inflammatory
response to Aβ stimulation [54, 55, 56]. In addition, the deficiency of TLR2 or CD14 in
AD mouse models attenuates plaque deposition by modulating the inflammatory milieu
[57, 58, 59]. In contrast, a loss-of-function mutation for TLR4 in APP/PS1 mice due to
a C3H background, increases Aβ deposition and cognitive deficits, but reduces microglial
activation in these mice [53, 60].
Activation states
Stimulation of microglia with Aβ, isolated post-mortem from AD and non-demented sub-
jects, leads to an increased expression of IL-1β, TNF-α, IL-6, and IL-12, indicating a pro-
inflammatory phenotype [61]. Combs et al. showed that treatment of neonatal murine
microglia with Aβ, co-cultured with embryonic neurons, results in neuronal death in-
duced by secreted TNF-α and enhanced production of reactive oxygen species (ROS)
[62]. However, in analogy to macrophages, microglia exhibit different activation pheno-
types possessing pro- or anti-inflammatory phenotypes [10, 20, 29, 63]. Stimulation with
LPS, TNF-α, IFN-γ or IL-1β results in a classical activation or M1 phenotype, whereas
stimulation with IL-4 or IL-13 leads to an alternative activation or M2 phenotype. A more
precise classification also suggests a third type (acquired activation) [63] or subtypes of
M2 type (M2a-c) [64, 65] activated by TGF-β and/or IL-10 stimulation.
M1 phenotype is characterized by the expression of pro-inflammatory cytokines, such
as IL-12, TNF-α, IL-1β or IL-6, and Th2 cell response mediators, like MHC II, CD86, in-
ducible nitric oxide synthase (iNOS). M2 type microglia or macrophages are characterized
by enhanced expression of anti-inflammatory cytokines (IL-10) and phenotypic markers,
such as macrophage mannose receptor (MMR), arginase-1 (Arg1), found in inflammatory
zone-1 (Fizz1), and a reduced expression of iNOS (Fig.1.5) [64, 65, 66]. These different
inflammatory phenotypes of microglia are related to either release of pro-inflammatory
cytokines and production of ROS leading to neuronal cell damage or phagocytosis of Aβ
and release of neurotrophic factors supporting neuronal protection [10, 67].
1.2.2 CNS-invading macrophages
Although microglia are the main mononuclear phagocyte population in the healthy CNS,
since they have a slow turnover it is suggested that peripheral monocytes infiltrate the
CNS by crossing the blood brain barrier (BBB) and renew the resident microglia popula-
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Figure 1.5: Microglial heterogenity
microglial cells can undergo different activation states after encountering Aβ peptides or
plaques (shown in red). The surveying microglia can be stimulated with either pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6) leading to classical activated M1 phenotype
(blue), or with anti-inflammatory cytokines (IL-10, TGFβ) resulting in alternative activated
phenotypes (M2a-c, yellow). M1 cells upregulate NOS2, CCL2, and ROS production, while
M2 types show reduced pro-inflammatory responsiveness, and upregulate FIZZ1, YM-1, man-
nose receptor or IL-10. Phenotype switching between these different states can be performed
using appropriate cytokines. Image from [64].
tion [20, 34, 68]. In AD, repopulation of CNS-resident micrcoglia cells, which are poten-
tially ineffective in Aβ clearance, by infiltrating monocytes/macrophages can contribute
to a better Aβ degradation. It was shown that stimulation of cultured microglia with
macrophage colony stimulating factor (M-CSF) decreases the lysosomal pH value compa-
rable to macrophages and results in a better Aβ degradation [48]. Using GFP-expressing
transplanted bone marrow (BM)-derived cells in irradiated APP mice, enhanced immi-
gration and differentation of BM-derived microglia in response to Aβ deposits could be
demonstrated [69, 70]. Further, it was shown that BM-derived microglia are essential
in restricting plaque progression [40, 43, 70]. Depletion of CD11b+ thymidine kinase
transgenic CNS-resident microglia in APP/PS1 mice by intracerebral administration of
ganciclovir shows that blood-derived microglia phagocytose Aβ [70]. The blockade of
TGF-β signaling in vitro and in vivo demonstrates enhanced phagocytic ability of periph-
eral macrophages but not microglia, and results in the attenuation of AD-like pathology
in Tg2576 mice by increased peripheral macrophage infiltration [40]. The deficiency of
CD45, an important immune regulatory protein expressed by all hematopoietic cells, but
not or only to a small extent by microglia, significantly increases neuronal loss and Aβ
burden in an AD mouse model [43].
One major source for tissue-infiltrating specialized macrophages are BM-derived blood
circulating monocytes [71]. These monocytes are characterized by and can be divided
into two subclasses of either Ly6ChighCCR2+CX3CR1− or Ly6ClowCCR2−CX3CR1+ ex-
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pression [71, 72, 73]. Ly6C is possibly involved in cell differentiation [74], whereas CCR2
and CX3CR1 are classical chemokine receptors mediating cell migration [75]. Ly6Chigh
monocytes are so-called inflammatory monocytes, that infiltrate and differentiate into
short-lived macrophages in inflamed tissues responsible for pathogen defense and wound
healing, whereas Ly6Clow monocytes are thought to renew tissue-resident macrophages
like Kupffer cells or microglia under physiological conditions [71]. Interestingly, El Khoury
et al. found by using CCR2−/− deficient Tg2576 mice a CCR2 dosage-dependent impaired
microglial accumulation and enhanced Aβ deposition in these mice [42]. Although it has
been shown, that BBB leakage caused by whole body irradition prior to BM transplantion
is crucial for CNS-infiltration [76], several studies demonstrated that CCR2+ cells are es-
sential in Aβ clearance [77, 78] and improved cognitive impairment in APP/PS1/CCR2−/−
non-irradiated mice [78].
1.2.3 Astrocytes, neurons, and oligodendrocytes
The most abundant cells in the CNS are astrocytes and beside microglia, they are consid-
ered to be a major source for inflammatory mediators in AD. Astrocytes accumulate in the
plaque periphery [79, 80] and express high levels of glial fibrillary acidic protein (GFAP), a
marker for reactive astrocytes. High expression of GFAP is linked to an increased expres-
sion of insulin-degrading enzyme (IDE), which is one of the main Aβ degrading factors
[28]. Furthermore, astrocytes express several receptors, that interact with Aβ, such as
RAGE, scavenger receptors (MARCO, SRA), and complement receptor C1q. High levels
of CCL2, which is a chemoattractant for adult astrocytes, are found within plaques [61].
In vitro studies of Aβ stimulated astrocytes showed increased expression of IL-1β, TNF-α,
and NO [81] as well as neuronal degeneration in co-cultures [82].
Neurons can express a number of molecules that mediate regulatory signals to microglial
cells. Some of these molecules are ligands of microglia surface receptors, e.g. loss of
CX3CL1 (fractalkine) - CX3CR1 (fractalkine receptor) signaling causes extensive neuronal
damage due to microglia hyperactivity [83]. Likewise, interactions of CD200 - CD200R
and CD47 - SIRPα downregulate microglia reactivity. Furthermore, several neuropeptides
and transmitters downregulate microglial production of pro-inflammatory cytokines to
prevent neuronal damage [20].
Oligodendrocytes are involved in neuronal transmission by producing myelin sheats of
axons and neuroprotection. Myelin lesions have been observed in AD patients and mouse
models for AD, and in vitro studies demonstrated Aβ toxicity for oligodendrocytes in cell
culture [84].
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1.3 Chemokines and chemokine receptors
Chemokines are important modulators of the innate and adaptive immune response. They
were originally named by abbreviating ”chemoattractant cytokines”, although today they
are counted as their own protein superfamily independent of the cytokine classification.
Chemokines are small secreted proteins with a molecular weight between 8-14 kDa. Pri-
marily found to be involved in cell attraction during inflammation and regulate also cell
trafficking in homeostasis, they can also modulate cell activation, proliferation, adhe-
sion and other cell processes [75]. Chemokines can be divided into four subclasses CXC,
CC, XC, and CX3C depending on their primary amino acid structur. CXC, CC, and
CX3C chemokines have four cysteine residues, which are either adjacent to each other
(the first two in CC subclass), separated by one amino acid (CXC) or by three amino
acids (CX3C). Chemokines of the XC subclass contain only two cysteine residues, that
are the second and the fourth ones in the other subclasses. The cysteine residues create
disulfide bonds, between the first and the third and the second and the fourth cystein
residue, that are responsible for a highly conserved tertiary structure [85]. They also
contain a C-terminal helix, three-stranded β-sheets (both are binding determinants), and
a disordered N-terminus with 6-10 amino acids, which is the key-signaling domain.
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Figure 1.6: Chemokine signaling
After chemokine binding, the active G protein dissociates from the CR and into the subunits
α and βγ. Activation of G proteins leads the inhibition of adenylyl cyclase and cell prolif-
eration, survival, adhesion, chemotaxis, etc. AC: adenylyl cyclase, CR: chemokine receptor.
Illustration adapted from [75].
Chemokines signal through G protein-coupled receptors (GPCR), belonging to the
seven-transmembrane domain receptor superfamily. The nomenclature of chemokine re-
ceptors refers to the subclass of their chemokine ligand (e.g. CCR). Up to now, around
50 chemokines and 20 chemokine receptors are known in humans [85]. In general, GPCR
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contain an extracellular N-terminal domain and an intracellular C-terminal domain and
inbetween seven transmembrane domains, which are connected by three extra- and three
intracellular loops. Signal transduction is mediated after a conformation change upon
ligand binding via a heterotrimeric Gαi protein. After ligand-binding and receptor acti-
vation, G protein switches from an inactive GDP-bound ground state to an active GTP-
bound state by nucleotide exchange. The active G protein dissociates into an α and a
βγ subunit leading to the initiation of several parallel running signal cascades. Gα·GTP
blocks cAMP production by the inhibition of adenylyl cyclase. Cellular effects of βγ sig-
naling are proliferation, synaptic transmission, cell adhesion, chemotaxis, etc. (Fig.1.6)
[75].
1.3.1 Chemokines in AD
Chemokines and their receptors are expressed in the fetal, neonatal and adult brain, so
that they are involved in developing processes and homeostasis of the brain. Under physi-
ological conditions, chemokines and their receptors can induce migration and proliferation
of neuronal progenitor cells, e.g. CCL5 and CXCL12 [75]. For example, disturbances in
CXCL12-CXCR4 interaction cause severe neurodevelopmental effects in mice [86].
Furthermore, chemokines are specifically up- or downregulated during pathological con-
ditions [75]. In AD brains, several chemokines and chemokine receptors are present.
CCR3, CCR5, CXCR2 and CXCR3 were found post-mortem in cortex and hippocampus
of AD patients by immunohistochemical analysis [75]. CCR3 and CCR5 showed a higher
expression on reactive microglia derived from AD brains in contrast to healthy controls,
while CCL3 and CCL4 were found on neurons, microglia and in a subpopulation of reac-
tive astrocytes [75]. In the cerebrospinal fluid (CSF) of some AD patients CCL2, CXCL8,
and CXCL10 have been found to be increased [87, 88]. Serum CCL2 levels were also
increased in patients with mild cognitive imapirments (MCI) and mild AD [89]. In vitro
studies on astrocytes and oligodendrocytes showed that Aβ is capable to induce CCL2
(also known as MCP-1) and CCL5 (RANTES), whereas human microglia isolated from
old AD and non-AD subjects express CXCL8, CCL2, CCL3, and CCL4 in presence of
Aβ dose-dependently [90]. In mouse models of AD, several studies were conducted to
unravel the role of chemokines and their receptors in the neuroinflammatory aspect of
AD development. Using CCR5 knock out mice (CCR5−/−), Lee et al. found that a defi-
ciency in CCR5 in aged (12-18 months old) mice caused astrocytic activation, increased
endogenous Aβ deposit, and severe memory functions [91]. Additionally, CCR5 ligand
CCL5 activates rat microglia in vitro to produce nitric oxide (NO) [92]. The chemokine
receptor CCR6 was found to be increased in the CNS of a triple transgenic 3xTg mouse
model, but also in peripheral immune organs, such as spleen and blood [93]. Since the
authors found the elevation of CCR6 in both, pre-symptomatic and symptomatic mice,
they suggested a possible role of CCR6 as biomarker for AD.
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Table 1.2: Chemokine receptors and ligands found in AD
AD: Alzheimer’s disease, CR: chemokine receptor, MD: Memory deficits, PBMC: peripheral
blood mononuclear cells, ↑: upregulated, ↓: downregulated.
CR or
chemokine Site of expression Effect in AD mouse models
CCR2 microglia, astrocytes, deficiency: plaques ↑, MD ↑
BM-derived microglia [75, 42] [42, 78]
CCR3 AD brain tissue [75] unknown
CCR5 AD brain tissue, deficiency: reactive astrocytes ↑,
microglia [75] endogenous Aβ ↑, MD ↑
CCR6 brain, spleen, PBMC unknown
in 3xTg mice [93]
CXCR2 AD brain tissue [75] unknown
CXCR3 AD brain tissue [75] unknown
CX3CR1 microglia [75] contradictory [94, 95, 96]
CCL2 CSF, serum, microglia overexpression: plaques ↑,
[87, 75] MD ↑ [97]
CCL3 neurons, microglia, unknown
astrocytes [75]
CCL4 neurons, microglia, unknown
astrocytes [75]
CCL5 astrocytes, oligodendrocytes [92] unknown
CXCL8 CSF [88], microglia [75] unknown
CXCL10 CSF [88] unknown
CX3CL1 neurons [98, 99] unknown
In contrast, investigation of CX3CL1 (fractalkine)-CX3CR1 signaling revealed a more
complex role of chemokines during AD progression. Recently, it was shown that CX3CR1
deficiency reduces Aβ load in two mouse models of AD while altering microglia cytokine
expression [94]. Furthermore, others showed at the same time the specific CX3CR1 knock-
out in microglial cells in a mouse model of AD protects against neuronal loss [95]. How-
ever, earlier findings of in vitro stimulation studies of microglia activation by Aβ or LPS
indicate a protective role of the CX3CR1 ligand fractalkine during microglia-mediated
neuroinflammation by blocking the production of IL-6, TNF-α, and NO [98, 99]. In a dif-
ferent mouse model of AD it was shown that CX3CR1 knock out increases cortical IL-6
level, which correlates with cognitive deficits in these mice [96]. Chemokines and their
receptors can also show opposite effects in AD pathogenesis. Overexpression of CCL2 in
Tg2576 mice enhances cognitive dysfunction and accelerates Aβ deposition [97], whereas
its receptor CCR2 leads to recruitment of peripheral macrophages with protective effects
in an AD mouse model [42]. Table 1.2 gives an overview of chemokine receptors and their
ligands found to be involved in AD.
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1.4 The CC chemokine CCL17
CCL17, originally named as TARC (thymus and activation-regulated chemokine), be-
longs to the CC chemokine subclass. It was found in 1996 to be constitutively expressed
in thymus and highly selective for T cells [100]. CCL17 is mainly expressed by mature
DCs found in several lymphoid and non-lymphoid tissues [101], but it was also found
in alternative activated macrophages in vitro upon IL-4 stimulation [102, 103], human
keratinocytes and fibroblasts [104]. The chemokine receptor for CCL17 is CCR4 [105],
which is expressed by Th2 cells, regulatory T cells (Treg), NK cells, DCs, basophils, and
platelets, but also by macrophages [106]. An interaction of CCL17 with CCR8 has been
discussed also [107], although others excluded CCL17 as chemoattractant and modulator
for CCR8high expressing CD4+ Th2 cells [108]. CCL17 is critically involved in recruit-
ment of Th2 cells in asthma [109], and regulation of mast cell [110] and cutaneous DC
migration [111] in skin diseases [112]. Further, it plays important roles in alternative
cross-presentation by DCs [113], control of Treg cell homeostasis in atherosclerosis [114],
and regulation of IL-23 production by CCR4+ DCs causing experimental autoimmune
encephalomyelitis (EAE), a mouse model for multiple sclerosis [115]. In a mouse model
for HIV-1-induced neurodegeneration ccl17 mRNA was found to be upregulated in the
frontal cortex of APPswe mice after chronic Tat exposure, suggesting a potential role in
neuroinflammation [116].
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2 Aim of this study
The majority of people over 70 years of age in the industrial countries are affected by
any dementia, and in most cases they received the diagnosis Alzheimer’s disease. Up
to now, no drug or other medication is available to stop this neurodegenerative process,
even less to reverse this process. Inflammatory processes are critically involved by cells
releasing neurotoxic or neurotrophic factors influencing survival of neurons and synapses,
and thereby cognitive behavior. Several chemokines and their receptors have been shown
to be upregulated in AD and play a crucial role in plaque deposition, microglia and
astrocyte activation, and cognitive behavior in ADmouse models. A deeper understanding
of the inflammatory mechanisms, regulated by chemokines and their receptors could give
raise for potential new targets for drug development. CCL17 is an inducible chemokine,
found to be upregulated under neuroinflammatory conditions in humans [117, 118] and
mice [116]. By the usage of a CCL17-deficient APPswe/PS1dE9 mouse strain (APP/PS1-
CCL17E/E) a potential role of CCL17 in the pathogenesis of AD should be investigated.
In the first part of the project, the behavioral phenotype of cognitive abilities and plaque
progression of APP/PS1-CCL17E/E was assessed. In the second part of the project, the
influence of APP/PS1 transgenity on CCL17 expression and the cellular source of CCL17
was analyzed. In the third part, a potential mechanism underlying the altered phenotype
of APP/PS1-CCL17E/E was investigated. Finally, the question was addressed, whether
CCL17 levels in the cerebrospinal fluid or the plasma of individuals could be used as a
biomarker for AD.
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3.1 Materials, chemicals, and buffers
3.1.1 Equipment
Analytical Balance Sartorius BP 2100, Elk Grove, IL, USA
Apotome ApoTome2, Zeiss, Jena, Germany
CCD camera Axiocam MRm, Zeiss, Jena, Germany
Cell count chamber Neubauer, CarlRoth GmbH,
Karlsruhe, Germany
Cell culture dishes Greiner Bio-one, Frickenhausen, Germany
Centrifuge Fresco17 Zentrifuge, Heraeus and
Multifuge 3SR, Heraeus, Thermo Scientific,
Langenselbold, Germany
Cryostate CM3050 S, Leica, Wetzlar, Germany
Electrophoresis apparatus PowerPac supply, BioRad, Mu¨nchen, Germany
Flow cytometer FACS-Canto I, FACS-Canto II, BD Bioscience,
Heidelberg, Germany
Homogenizers Precellys R© 24, Bertin Technologies, Erlangen,
Germany
Ultra-Turrex R©, IKA Werke, Staufen, Germany
Ultrasound homogenizer, Bandelin Sonoplus,
Berlin, Germany
Incubator CB210, Binder, Tuttlingen, Germany
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Magnetic stirrer MR3001, Heidolph, Schwabach, Germany
Microscope Axioplan 2, Zeiss, Jena, Germany
PCR Cycler 7900 HAT Fast Realt-Time PCR System,
Applied Biosystem, Carlsbad, CA, USA
Photometer NanoDrop ND-1000 Spectraphotometer,
Wilmington, DE, USA
Petri dishes Greiner, Bio-one, Frickenhausen, Germany
Polyamide mesh (40 µm) VWR International, Darmstadt, Germany
Polypropylene vials (15, 50 ml) BD Bioscience, Pharmingen,
San Diego, CA, USA
Polystyrene vials (5 ml) BD Bioscience, Pharmingen,
San Diego, CA, USA
Safe-lock vials (0.5, 1.5, 2 ml) Eppendorf, Hamburg, Germany
SlideA-Lyzer mini dialysis Pierce, ThermoFisher Scientific,
cassette (3.5 kD) Rockford, IL, USA
Superfrost Plus R© slides Menzel-Gla¨ser, Braunschweig, Germany
Thermo mixer Eppendorf, Hamburg, Germany
Thermo cycler ICycler, BioRAD, Mu¨nchen, Germany
Tissue culture hood HERsafe, Thermo Scientific,
Langenselbold, Germany
Plate photometer MRX TC II, Dynex Technologies,
Denkendorf, Germany
24-well-plate BD Bioscience, Pharmingen,
San Diego, CA, USA
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96-well-plate Greiner, Bio-one, Frickenhausen, Germany
384-well-plate Applied Biosystems, Carlsbad, CA, USA
3.1.2 Antibodies, chemicals, and primers
Antibodies
Table 3.1: List of antibodies used in this study. Abcam, Cambridge, UK; AbD Serotec, Du¨sseldorf,
Germany; BD Pharmingen, San Diego, IL, USA; Biozol, Eching, Germany; eBioscience, Frank-
furt, Germany; Invitrogen, Darmstadt, Germany; Millipore, Schwalbach, Germany; Santa Cruz
Biotechnol., Heidelberg, Germany; SIGMA-Aldrich, Steinheim, Germany; Signet Laboratories,
Dedham, MA; USA
1st Antibody Species Host Dilution Company
amyloid beta 6E10 human mouse 1:1000 Signet Laboratories
β-actin mouse mouse 1:1000 SIGMA-Aldrich
CCR2 mouse goat 1:20 AbD serotec
CD11b-APC mouse rat 1:100 eBioscience
CD11b-bio mouse rat 1:100 BD Pharmingen
CD11b-eFluor450 mouse rat 1:100 eBioscience
CD11b-PE mouse rat 1:100 BD Pharmingen
CD11c-AlexaFluor647 mouse hamster 1:200 Biozol
CD16/32 mouse rat 1:300 Biozol
CD40-PE mouse rat 1:100 eBioscience
CD45.2-AlexaFluor647 mouse mouse 1:100 Biozol
CD45-eFluor450 mouse rat 1:100 eBioscience
EEA1 mouse rabbit 1:200 Abcam
GFAP-bio mouse rabbit 1:100 Santa Cruz Biotechnol.
Ly6C-bio mouse rat 1:100 BD Pharmingen
MMR-bio mouse rat 1:100 Biozol
NeuN-bio mouse rabbit 1:100 Millipore
TCR-bio mouse hamster 1:200 eBioscience
2nd Antibody
anti-goat-AlexaFluor647 goat rabbit 1:200 Invitrogen
anti-rabbit-bio rabbit goat 1:200 Invitrogen
anti-rabbit-Cy3 rabbit goat 1:300 Invitrogen
Streptavidin-APC - - 1:200 Biozol
Streptavidin-Cy3 - - 1:200 Invitrogen
Streptavidin-PerCP-Cy5.5 - - 1:200 BD Pharmingen
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Cell culture stimulants & enzymes
Table 3.2: List of cell culture stimulants & enzymes used in this study. Peptide Specialty
Companies, Heidelberg, Germany; Roche, Grenzach, Germany; R&D systems, Wiesbaden-
Nordenstadt, Germany; SIGMA-Aldrich, Steinheim, Germany
Stimulant End concentration
or enzyme or dilution Company
Amyloid beta peptide 515 nM Peptide Specialty Companies
Collegenase (CNS) 1:10 Roche
Collegenase (LN, spleen) 1:100 SIGMA-Aldrich
DNase (CNS) 1:10 Roche
DNase (LN, spleen) 1:100 SIGMA-Aldrich
IFNγ 20 ng/ml R&D systems
LPS 100 ng/ml SIGMA-Aldrich
Proteinase K 0.6 % (v/v) Roche
ELISA and assay kits
Table 3.3: ELISA and assay kits used in this study. BD Pharmingen, San Diego, CA, USA; eBio-
science, Frankfurt, Germany; Invitrogen, Darmstadt, Germany; Linaris, Dossenheim, Ger-
many; PerkinElmer, Rodgau, Germany; R&D systems, Wiesbaden-Nordenstadt, Germany;
ThermoFisher, Rockford, IL, USA
Kit Company
Peptide labeling kit ThermoFisher
BCA assay ThermoFisher
Cytofix/Cytoperm BD bioscience
human Aβ1-40 Invitrogen
human Aβ1-42 Invitrogen
mouse CCL2 ELISA eBioscience
human CCL17 ELISA R&D systems
mouse IL-6 ELISA eBioscience
mouse IL-10 ELISA eBioscience
Perm/Wash buffer BD bioscience
TSA Enhancer System PerkinElmer
VectaShield DAPI Linaris
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PCR primers
Table 3.4: Primersequences for PCR. All PCR primers were purchased from TIBMolBiol, Berlin,
Germany
Primer Sequence
PSEN-1 (forward) ggT CCA CTT CgT ATg CTg
PSEN-1 (reverse) AAA CAA gCC CAA Agg TgA T
control (forward) gTT TAA ACg TTT TCg Cgg ggg CCT gCg gTg CAT CAA g
control (reverse) gTT TAA ACC CgC CAA TgC CCA AgA A
Taqman assays
Table 3.5: List of Taqman gene assays used in this study. All Taqman primer were purchased from
Applied Biostystems, Carlsbad, CA, USA
Target gene Assay ID Cycle steps
arg1 Mm00475988 m1 40
ccl17 Mm00516136 m1 40
ccl22 Mm00436439 m1 40
ccr2 Mm00438270 m1 40
ccr4 Mm00438271 ml 45
gapdh Mm99999915 gl 40, 45
ide Mm00473077 m1 40
il-1β Mm01336189 m1 40
il-6 Mm00446190 m1 40
il-10 Mm99999012 m1 40
inos Mm00440485 m1 40
mmp-9 Mm00442991 m1 40
marco Mm00440265 m1 40
nep Mm00485028 m1 40
rage Mm01134790 g1 40
tgf-β1 Mm00441724 m1 40
tnf-α Mm00443258 m1 40
ym-1 Mm00657889 mH 40
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3.1.3 Buffers and solutions
All reagents used in this work were purchased from Carl Roth (Karlsruhe, Germany),
Invitrogen (Darmstadt, Germany), Merck (Darmstadt, Germany), or SIGMA-Aldrich
(Steinheim, Germany). Exceptions are noted seperately.
Cell culture medium DMEM (4.5 g/l glucose)
10 % (v/v) FCS
Digestion solutions for CNS 1:10 Collagenase (in cell culture medium)
and
1:10 DNase (in cell culture medium)
Digestion solution for peripheral Collagenase (1:100) and DNase (1:16)
lymphoid tissues (in cell culture medium)
ELISA washing buffer 1x PBS
0.05 % (v/v) Tween-20
ELISA stop solution 1 M H3PO4
FACS buffer 1x PBS (pH = 7.2)
2 % (v/v) FCS (inactivated)
Lysis buffer 450 µl TNE buffer
50 µl 10 % (w/v) SDS
3 µl Proteinase K
Macrophage culture medium RPMI 1640
15 % (v/v) M-CSF
10 % (v/v) FCS (inactivated)
1 % (v/v) Penicillin / Streptomycin
0.1 % (v/v) β-Mercaptoethanol
Microglia culture medium DMEM (4.5 g/l glucose)
10 % (v/v) FCS (inactivated)
1 % (v/v) Penicillin / Streptomycin
1 % (v/v) MEM
0.1 % (v/v) β-Mercaptoethanol
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Narcotic solution 5 ml Xylariem
2.5 ml Ketamin
52.5 ml 0.9 % (w/v) NaCl
Percoll gradient solutions 70 % (v/v) percoll (in cell culture medium)
30 % (v/v) percoll (in FACS buffer)
RIPA buffer 100 mM Tris (pH = 8)
150 mM NaCl
0.5 % (w/v) IPEGAL
0.2 % (w/v) SDS
(prior to use: 1 tablet Complete Mini
Protease Inhibitor per 10 ml buffer)
10 % SDS 100 g SDS per 1 l
pH = 7.2
TAE buffer 40 mM Tris acetate
1 mM EDTA
TE buffer 10 mM Tris-HCl
1 mM EDTA
pH = 7.6
TNE buffer 10 ml 1 M Tris (pH 8.0)
20 ml 5 M EDTA
2 ml 0.5 M EDTA
make up to 1 l with H2OmilliQ
3.1.4 Statistics
All data represent mean ± standard error of the mean (SEM). If not otherwise stated,
statistical data analysis with Student’s t-test or 1-way-ANOVA with Bonferroni post-hoc
test was performed using GraphPad Prism (Version 4.0a or 5.0a, GraphPad Software
Inc.). All data were analyzed by KS normality test (alpha = 0.05).
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4.1 Mouse strains and animal housing
The APP/PS1-CCL17E/E mouse strain were generated by breeding APPswe (K594N/
M595L)/PS1dE9 mice (C57BL/6J background, Charles River Laboratories) with CCL17-
deficient mice (CCL17E/E). CCL17E/E mice are homozygous for a knock-in of an enhanced
green fluorescent protein (EGFP) cassette into the gene encoding region of the ccl17 locus
under the endogenous mouse ccl17 promoter [101].
Animals were group-housed under temperature-controlled conditions with a 12 h light-
dark cycle and had free access to food and water. All experiments were performed ac-
cording to the German national animal care guidelines (Tierschutzgesetz Deutschland)
and approved by the local committee for animal studies (Landesamt fu¨r Natur, Umwelt
und Verbraucherschutz NRW).
4.2 APP/PS1 genotyping
APP/PS1 mice were bred heterozygous, for this genotyping for wt or transgene expres-
sion was needed. Tail tissue was obtained from mice 3-4 weeks after birth and incubated
in 500 µl lysis buffer at 56◦C overnight. DNA was extracted by adding 500 µl of phe-
nol/chloroform/isoamylalcohol (25:24:1). After centrifugation at 13,000 rpm for 5 min
the supernatant was taken and the DNA was precipitated by adding 900 µl ethanolabs..
After centrifugation at 13,000 rpm for 5 min, the supernatant was discarded and the
pellet was washed with 500 µl 70 % (v/v) ethanol and dried for 20 min. The pellet was
resuspended in 200 µl TE buffer. The DNA concentration was measured at λ = 260
nm using NanoDrop spectralphotometer. Purity of DNA sample was given by a ratio of
A260/280nm = 1.8 and a ratio of A260/230nm = 2.0. The APP/PS1 genotype was determined
by polymerase chain reaction (PCR). DNA concentration was diluted to 50 - 100 ng/ml.
For each sample following concentrations were used:
1 µl sample
9.5 µl H2O
12.5 µl 2x GoTaq Green Master Mix
1 µl PSEN-1 (forward primer)
1 µl PSEN-1 (reverse primer)
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The PCR product has a size of 536 base pairs (bp). DNA from wildtype mice did not
produce a band, for this an internal DNA control was needed:
1 µl sample
9.5 µl H2O
12.5 µl 2x GoTaq Green Master Mix
1 µl DNA control (forward primer)
1 µl DNA control (reverse primer)
Both reaction mixtures were run under following conditions:
Cycle 1 (1x): Denaturation: 95◦C, 5 min
Cycle 2 (40x): I. Denaturation: 95◦C, 1 min
II. Annealing: 63◦C, 1min
III. Elongation: 72◦C, 1 min
Cycle 3(1x): Final Denaturation: 72◦C, 10 min
15◦C, ∞
The samples were load on a 1 % (w/v) agarose gel, run with 120 V for 50 min, and
incubated in a 0.16 % (w/v) EtBr bath for 20 min.
4.3 Behavioral phenotyping
Survival
Survival of animals was controlled every week for 6 months starting at age of 3 months.
Data were analyzed using Kaplan-Meier survival curves.
Morris water maze
Performing the Morris water maze (MWM) spatial learning and memory abilities of mice
can be assessed. The test consists of two tasks, the acquisition phase and the probe trial.
Mice were first tested for four consecutive sessions per day over seven days (acquisition
phase), and on day 8 mice were tested in one session (probe trial). During the acqui-
sition phase a platform was hidden in a milky water bath suspension at a fixed spatial
location in a target quadrant (T). All quadrants (T = target, O = opposite, L = left, R
= right) were marked with four points equally distributed along the wall. On day one
and two animals were placed in quadrant O for each session. From day 3 to day 7, mice
were placed in O, L, R, and T in the four sessions. Escape latency for all sessions was
measured. During the probe trial, the platform was removed and the time to reach the
target quadrant and time spent in the target quadrant was measured.
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4.4 Organ withdrawal and isolation methods
Brain removal for protein isolation and immunohistochemistry
Mice were anesthetized by i.p. injection of 500-1,000 µl narcotic solution, and afterwards
fixed on a polystyrene plate lying on the back. Abdomen and thorax were opened, and
the mice were transcardially perfused with 20 ml of ice-cold PBS. The skull was opened,
brain was removed and cut into the hemispheres. For protein isolation, the left hemisphere
was immediately snap-frozen in N2(liq.) and stored at -80◦C. For histochemistry, the right
hemisphere was fixed in 4 % (w/v) PFA overnight at 4◦C, followed by an incubation in
20 % (w/v) sucrose for 4-5 h, embedded in TissueTek, and stored at -80◦C.
Isolation of cortex and hippocampus
After cervical dislocation, cortex was isolated and snap-frozened in an isopentan/dry ice
mixture. After the removal of the cortex the hippocampus became visible and could also
be isolated and snap-frozened. Samples were stored at -80◦C.
Serum preparation
Blood samples were taken from living animals by a single cut of the tail vein. Mice were
pre-warmed by an infrared lamp, fixed in a small tube, and the tail vein was cut. A
volume of up to 500 µl blood from each mouse was collected. The samples were stored
at room temperatur for 30-60 min. After clotting the serum was clearly separated and
centrifuged with 13,000 rpm for 30 min at 4◦C. The supernatant was stored at -20◦C.
Isolation of intracerebral leukocytes
Mice were anesthetized and perfused as described above. Brains were removed and placed
in 5 cm2 Petri dishes. Per brain, 1 ml of collagenase digestion solution was added and
the brains were further minced by pipetting up and down with a syringe containing 4 ml
cell culture medium. Brains were incubated at 37◦C and 5 % CO2 for 45 minutes. One
ml of DNase digestion solution per dish was added and the brains were incubated again
for 45 min (37◦C, 5 % CO2). After the digestion the single cell suspension was pipetted
through a 100 µm filter, and the digestion solution was inhibited by diluting with cell
culture medium up to 50 ml. The cell suspension was centrifuged with 15000 rpm for 7
min at 4◦C and the pellet was dissolved in 20 ml of 70 % (v/v) percoll solution. 20 ml
of 30 % (v/v) percoll solution was carefully added to get a two-phase density gradient
system. The samples were centrifuged with 2,100 rpm for 25 min at room temperature
without brake. Intracerebral leukocytes are located at the interface of the two phases and
can be seen (depending on the number of cells) as a white ring. 10 ml of the interphase
were placed into a fresh tube and 40 ml of cell culture medium were added. After cen-
trifugation with 1,800 rpm for 10 min at 4◦C, the pellet was dissolved in 1 ml FACS buffer
for flow cytometric analysis. Cells were counted manually using a Neubauer chamber.
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Isolation of peripheral blood mononuclear cells
Blood samples were taken as described above (serum preparation), but to avoid blood
clotting a volume of around 500 µl blood from each mouse was collected in a 1.5 ml vial
containing 20 µl heparin. 4 ml of ficoll were covered with 450 µl of blood and centrifuged
with 2,000 rpm for 20 min at room temperatur without brake. Isolated mononuclear cells
appeared as a white ring in the upper part of the gradient solution. 1 ml of the cell sus-
pension was placed into a fresh tube, filled with FACS buffer up to 1.5 ml and centrifuged
with 6,000 rpm for 5 min at 4◦C. The pellet was resuspended in 500 µl FACS buffer, cells
were counted and stained for flow cytometric analysis. Cells were counted manually using
a Neubauer chamber.
Isolation of cells from spleen or lymph nodes
Mice were perfused as described above. Spleen and mesenterial lymph nodes (LNmes) were
isolated first. Then, parietal peritoneum was carefully separated from the abdominal wall
and inguinal LNing were isolated. Axillary LNax and cervical LNcerv were isolated after
removal of the ambient tissue. Spleen and LN were placed into 10 and 5 cm2 Petri dishes,
minced and digested in 10 and 5 ml collagenase/DNase solution for 45 min at 37◦C and
5% CO2. Single cell suspension was made by pipetting up and down and filtering through
a 100 µm filter. Cells were washed by adding ice-cold PBS up to a final volume of 50 ml,
counted, and centrifuged with 1500 rpm for 7 min at 4◦C. The pellet was resuspended in
1 ml FACS buffer. Cells were counted manually using a Neubauer chamber. Then, cells
were stained for flow cytometric analysis.
4.5 Generation of primary mouse cell cultures
Generation of bone marrow-derived macrophages
After cervical dislocation, skin-free femur and tibia were separated and opened under
cell culture-sterile conditions. Bone-marrow was flushed out with ice-cold PBS using a
10 ml-syringe, collected per mouse in a 10 cm2 Petri dish and resuspended using a glas
pipette. The single cell suspension was filtered through a 100 µm filter, cells were washed
by adding ice-cold PBS up to an end volume of 50 ml, counted, and centrifuged with 1,500
rpm for 10 min at 4◦C. The cell pellet was resuspended in macrophage culture medium,
and placed into an uncoated 10 cm2 Petri dish to yield a cell concentration of 1.5x105/ml
in 10 ml of total medium. Cells were incubated for 6 days at 37◦C and 5 % CO2. On
day 3, 5 ml of freshly prepared medium were added. On day 6 cells were used for either
stimulation or phagocytosis assays.
Generation of primary microglial cell cultures
Brains of 0-5 days old pups (CCL17E/E and WT) were dissected out, placed in ice-cold
Hanks’ buffer while meninges were removed. Isolated cortices were mechanically minced
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to a single-cell suspension using a pipette. After centrifuging for 1,500 UpM for 5 min
at 4◦, cell pellets were resuspended in 1 ml neonatal microglia cell culture medium and
2-3 pups of each genotype were cultured in one cell culture flask. Cells were cultured
overnight at 37◦C and 8 % CO2. On the next day, medium was changed and cells were
further cultured for 2-3 weeks until a specific cell density was reached. Medium was
changed every 3rd day.
4.6 Amyloid-β peptide labeling
Synthetic Aβ1-42 was labeled with DyLightTM649 prior to phagocytosis assay according to
manufacturer’s recommendations. Afterwards, purification of Aβ-DyLight649 (4.5 kDa)
from unlabeled peptide was performed by using Slide-A-Lyzer mini dialysis cassette for
petides > 3.5 kDa. The Aβ-DyLight649 solution was placed into the dialysis cassette and
incubated for 2 h in HBSS on a stirrer (RT, dark). Purified Aβ-DyLight649 solution was
stored at -20◦C before use.
4.7 Phagocytosis and stimulation assays
Cells were stimulated with LPS (100 ng/ml) for 16 h either in culture flasks or dishes. For
phagocytosis, cells were seeded in 24-wells-plate (2 x 105 cells/well) and settled overnight
in fresh medium before experiments. AlexaFluor649-labeled Amyloid beta (1-42) (515
nM) was let to be phagocytosed for 1 h, afterwards medium was replaced by Aβ-free
medium. Chasing of Aβ degradation was done, starting from medium change at 0 h, 1 h,
3 h, and 6 h or up to 24h. Internalization of AlexaFluor649-labeled Amyloid beta (1-42)
was performed within 15 min. Cells were harvested, stained, and analyzed either by flow
cytometry or microscopy.
4.8 Protein isolation and quantification
Protein isolation
Frozen brains were weighed and 1 ml RIPA buffer per 150 mg brain was added. Brains
were homogenized with the Ultra-Turrax for 10 s on ice, sonicated first with 1x 20 s, 30
% cycles, 100 % power, second with 1x 20 s, 60 % cycles, 100 % power, and chilled on
ice for 20 min. Then the samples were centrifuged with 13,300 g for 30 min at 4◦C. The
supernatant was collected aliquoted in 200 µl aliquotes and stored at -80◦C.
Protein quantification by BCA assay
For total protein concentration a commercial available kit was used. The BCA assay
based on the biuret reaction. Bicinchoninic acid (BCA) forms in the presence of pro-
teins and copper ions a color-intense stable complex with light-sensitivity at λ = 562 nm.
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Samples were diluted 1:50 and the total protein concentration was measured following
manufacturer’s instructions.
Enzyme-linked immunosorbent assays (ELISA)
ELISA based on the principle of antibody-mediated detection of a specific protein in a
complex matrix such as plasma, cell culture supernatants, or tissue homogenates. The
concentration of the target protein is directly correlated to a light-sensitive detection
signal given by enzymatically oxidized 3,3’,5,5’-tetramethylbenzidine (TMB). Detection
signal is measured at λ = 450 nm. Human amyloid beta 42 and 40 (hAβ42, hAβ40) were
detected in brain homogenates and mouse serum following manufacturer’s instructions.
Serum samples were assayed undiluted, whereas for brain homogenates the dilution factor
was determined individually for each aging group. For the determination of cytokines or
chemokines the samples were diluted individually for each target protein and the concen-
tration was determined according to the manufacturer’s instructions.
Western blot
Right hemispheres were homogenized in 0.325 M sucrose (in PBS with phosphatase/pro-
tease inhibitor) by sonification: 20x 70 %, 20s on ice, repeated 5x, 30 min on ice inbetween.
Samples were centrifuged (13.000 rpm, 45 min, 4◦C) and supernatants stored at -80◦C
until analysis. Samples, gel electrophoresis, and western blot were performed according to
manufacturer’s instructions for reduced samples. For SDS-PAGE following materials or
chemicals were used: 4-12 % NuPAGE Novex Bis-Tris gel, NuPAGE MES SDS running
buffer and Novex Sharp Prestain Standard. Anti-human amyloid beta 6E10 (1:1000 in
PBS-T (0.02 % NaN3)) was incubated overnight at 4◦C and the signal was developed
using enhanced chemiluminescence (ECL). Data were analyzed by BioRad QuantityOne
software.
4.9 RNA isolation and qRT-PCR
RNA isolation
RNA from organ tissue (cortex, hippocampus) was isolated using TRIzol protocoll. Sam-
ples were transferred into MagNA Lyser tubes, 800 µl TRIzol were added, and for the
homogenization the Precellys homogenizator (program 2) was used. Samples were cen-
trifuged with 11,400 rpm for 5 min at 4◦C, the supernatant was transferred into a new
tube, 160 µl BCP were added, and both solutions were roughly mixed for 30 s. After
incubation at room temperature for 3 min, samples were centrifuged with 11,400 rpm for
10 min at 4◦C. The RNA-containing phase (aqueous) was transferred into a new tube and
400 µl isopropyl alcohol were added. Samples were mixed, incubated for 10 min at 4◦C,
and centrifuged with 11,400 rpm for 10 min at 4◦C. The RNA pellet was washed with 1
ml 75 % ethanol and centrifuged with 11,400 rpm for 5 min at 4◦C three times. Pellets
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were dried at 50◦C for 10 min and dissolved in 20 µl RNase-free water by incubation for
20 min at room temperature. RNA concentration was measured at λnm = 260 nm using
a NanoDrop spectralphotometer and samples stored at -80◦C. Purity of RNA sample was
given by a ratio of A260/280nm = 2 and a ratio of A260/230nm = 2.0.
For RNA isolation from cell culture (neonatal microglia), cells were harvested, cen-
trifuged with 4,500 rpm for 5 min 4◦C, pellets were resuspended in 800 µl TRIzol and
mechanically homogenized using a pipette. Further protocol steps were similar to as de-
scribed above.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Complementary DNA (cDNA) from isolated RNA was made using the RT-PCR method,
based on the enzymatic ability of reverse transcriptase to transcribe RNA into single-
strand DNA. For the reaction mixture following conditions were used:
Starting reaction solution:
x µl RNA (= 5 µg)
y µl (= 11 - xµl) RNase-free water
1 µl OligodT
1 µl dNTP
Samples were pre-heated in a cycler using the follwing program:
65◦C, 5 min
4◦C, ∞ ⇒ add 6 µl 5x First-Strand buffer/DTT per samples
42◦C, 2 min
4◦C, ∞ ⇒ add 1 µl SuperScript II Reverse Transcriptase
42◦C, 50 min
70◦C, 15 min
4◦C, 2 min
After the reaction was completed, samples were diluted 1:6 with RNase-free H2O to a
final concentration of 42 ng/µl cDNA and stored at -20◦C.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Quantitative real-time PCR is a widely used method for detection of mRNA expression
levels within tissues or cells. Based on the principle of common PCR, e.g. amplification of
a DNA sequence by an active DNA polymerase, the amount of DNA products is tracked
by a fluoresence signal. During the PCR, fluorescence-labeled gene-specific primers are
degraded at their 5’ end by the Taq DNA polymerase, which leads to a release of the fluo-
rochrome from a quencher molecule. The emitted fluorescence signal is directly correlated
to the initial mRNA expression level and the target cDNA within the sample. Following
conditions for the reaction mixture were used:
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Reaction solution:
2 µl cDNA (= 84 ng)
7 µl RNase-free water
10 µl 2x Taqman Gene Expression Master Mix
1 µl 20x Taqman Gene Expression Assay
2 µl cDNA of each sample were pipetted into a well of a 384-well plate, 18 µl of master
mix were added and the plate was read in a PCR cycler by the program SDS 2.2 for
relative quantification. Each sample was run in triplicates and for each gene one water
control was run. Standard program conditions were as follows:
Step 1: 95◦C (10 min)
Step 2 (40 cycles): 95◦C (15 s), 60◦C (1 min)
∆CT values were calculated by substracting the CT values of the internal standard
gene (GAPDH) and 2−∆CT values were calculated.
4.10 Histochemistry and immunofluorescence
Cryo section
TissueTek-embedded frozen brains were sagitally sliced into 12 µm slices. Starting from
a lateral depth of 1.92 mm to a lateral depth of 0.24 mm every second slice was taken on
Superfrost microscope slides (three slices / slide). Slides were stored at -20◦ until staining.
Thioflavin S staining
Fibrillary proteins, such as amyloid aggregates, containing β-sheet-rich structures can be
stained by either Thioflavin T (Fig. 4.1) or Thioflavin S. Thioflavin S is a mixture of
benzothiazol dye isoforms. These chemical compounds exhibit a red shift of fluorescence
emission by binding to amyloid fibrils [119, 120].
Figure 4.1: Molecular structure of Thioflavin T
Binding to amyloid fibrils results in enhanced fluorescent emission.
Brain slices were thawed for 5 min at 4◦, washed for 5 min in PBS, and incubated in
280 ml of 0.025 % (w/v) Thioflavin S solution (1:2 EtOH/PBS). Slices were washed twice
with PBS for 5 min and subsequently embedded in Fluoromount G (Southern BioTech,
Birmingham, AL, USA). Cover slips were fixed with nail polish.
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Immunohistochemistry
Brain slices were stained with fluorophore-labeled secondary reagents (strepatividin-Cy3
or streptavidin-APC). As primary antibodies were used: anti-GFAP-bio, or anti-NeuN-
bio. Signal enhancement was performed using TSA tyramide signal amplification system
in accordance with manufacturer’s instructions. Endogenous peroxidases were neutralized
by incubating with 1 % H2O2 solution (in PBS, 0.1 % NaN3) for 30 min at RT on a stirrer.
Blocking solution was incubated for 2 h at RT, followed by sequential blocking steps for
avidin and biotin for 20 min each (RT, dark). Biotinylated primary antibody was incu-
bated overnight (1:100, 4◦C, dark). After incubation with streptavidin-HRP for 30 min
(1:200, RT, dark), signal enhancement was performed by adding HRP substrate solution
(bio-tyramide, 1:100) to slices for 8 min. Afterwards, slices were incubated with secondary
antibody (streptavidin-Cy3 or -APC) for 30 min (RT, dark). Slices were washed twice
with PBS for 5 min and subsequently embedded in VectaShield DAPI. Cover slips were
fixed with nail polish.
Immunocytochemistry
Staining of cells from phagocytosis assay was performed in 24-well plates. Cells were
fixed by incubating with 500 µl cytofix/cytoperm for 20 min on ice in the dark. After
a washing step (500 µl perm/wash buffer, 5 min, on ice, dark), cells were incubated in
300 µl blocking solution (1:100 CD16/32, 10 % goat serum in perm/wash buffer) for 15
min on ice in the dark. Cells were washed and incubated in primary antibody solution
(1:100 EEA1 in perm/wash buffer) for 30 min on ice in the dark. After washing, cells
were incubated in a secondary antibody solution (1:300 anti-rabbit-Cy3 in perm/wash
buffer) for 30 min on ice in the dark. Cells were embedded in VectaShield DAPI. Cover
slips were fixed with nail polish.
Quantitative fluorescence analysis
Images of cortex (frontal, parietal, occipital) or hippocampus were taken (20x magnifica-
tion) and analyzed by ImageJ 1.42q. Background was substracted, same threshold was
set for all images and area fraction or mean size of particles was measured. 3-5 mice per
group and 5 slices per mouse were analyzed. Z-stack pictures (63x magnification) of cells
were taken and amyloid beta-positive particles within the cells were analyzed by ImageJ
1.42q. Three images of the center of cells were analyzed by ImageJ 1.42q using analyze
particles mode (triplicates / mouse, three mice / group).
4.11 Flow cytometry
Sample preparation
Cells from isolation procedure (as described above) or phagocytosis assay were washed in
1 ml of FACS buffer by centrifuging with 4,500 rpm for 5 min at 4◦C. The cell pellet was
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resuspended in 45 µl blocking buffer (CD16/32 in FACS buffer, 1:300), and incubated for
15 min on ice. Cells were washed by adding 500 µl FACS buffer and centrifuged with 4,500
rpm for 5 min at 4◦C. Cells were resuspended in 45 µl mixed primary antibody solution
(1:100) and stained for cell surface markers by incubating for 15 min in the dark on ice.
After a subsequent washing step, cells were incubated in 45 µl secondary antibody solution
(1:200) for 15 min in the dark on ice. Cells were washed, centrifuged and resuspended
in either 300 µl (intracerebral leukocytes), 500 µl (peripheral blood mononuclear cells),
or 1 ml (cells from spleen or lymph nodes). Cell suspensions were filtered through a 40
µm filter into FACS tubes and measured immediately. Data analysis were performed
using FlowJo 887. Absolut numbers of cell populations were calculated by multiplying
the percentages with total cell numbers divided by 100.
4.12 Human samples
Cerebrospinal fluid (CSF) and plasma samples were kindly provided and collected by the
Department of Psychiatry and the Department of Neurology of the University Medical
Center Bonn (UKB). Samples were stored at -80◦C and -20◦C, respectively until mea-
surement, thawed on ice, and human CCL17 protein concentration was determined using
human CCL17/TARC ELISA following manufacturer’s instructions. 50 µl of undiluted
sample, standard or control were add per well. All samples were run in triplicates. Protein
concentration was measured at λ = 450 nm, wavelength correction was performed at λ =
570 nm.
4.13 Integrated projects and cooperation partners
Christina Mu¨ller and Ramona Go¨hrs were supervised during this thesis for their medical
and diploma thesis, respectively. Experiments involving NeuN staining, GFAP and CD11b
immunofluorescence staining were performed by Christina Mu¨ller in the context of her
medical thesis. Ramona Go¨hrs performed during her diploma thesis the phagocytosis
assay, IL-6 and IL-10 ELISA of neonatal microglial cells. The behavioral analysis for
learning and memory was performed in cooperation with O¨nder Albayram and PD Dr.
Andras Bilkei-Gorzo. The western blot analysis of Aβ oligomers and APP expression
was done in a cooperation with Ilker Karaca and Prof. Dr. Jochen Walter from the
Department of Neurology, University of Bonn.
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5.1 Analysis of CCL17-deficient APP/PS1 mice
Investigation of the role of CCL17 in Alzheimer’s disease was performed by crossing APP-
swe (K594N/M595L)/PS1dE9 mice, a common mouse model for AD [19], with CCL17-
deficient mice (CCL17E/E). Behavioral analysis was conducted in APP/PS1-CCL17E/E
and APP/PS1 mice at 12-14 months of age (hereafter referred to as ”aged” mice). Aβ
progression was followed in young (four to six months), middle-aged (nine months), and
aged APP/PS1-CCL17E/E and APP/PS1 mice. Characterization of the neuroinflamma-
tory response was performed in aged mice, when plaque load and cognitive deficits were
fully developed in APP/PS1 mice [17, 129, 130]. WT and CCL17E/E mice were used as
AD-negative controls (”non-tg”).
5.1.1 APP/PS1-CCL17E/E mice exhibit WT-like survival and
behavioral phenotype
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Figure 5.1: Survival analysis of APP/PS1-CCL17E/E, APP/PS1, and WT mice
Diagram shows survival curves of APP/PS1-CCL17E/E (black squares), APP/PS1 (black
quadrants), and WT (open quadrants). Each data point represents an occasion of death.
Survival was controlled each week between 3 and 9 months of age. Given are Kaplan-Meier
survival curves for each group. Data analysis: Log-rank (Mantel-Cox) Test. (n = 9-16 mice/-
group)
It has been shown that transgenic APPswe(K594N/M595L)/PS1dE9 mice have a 35 %
higher pre-mature death rate before six months of age than age-matched WT mice [129].
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To test whether the defiency of CCL17 leads to an altered mortality, the survival of
APP/PS1-CCL17E/E, APP/PS1 controls and WT mice from three months to nine months
of age was evaluated. As shown in Fig.5.1, APP/PS1 mice had a death rate of 25 % within
this time, whereas WT mice showed a mortality rate of 11 %. Interestingly, APP/PS1-
CCL17E/E mice had a similar (15 %) death rate like WT mice in contrast to APP/PS1
controls.
Next, the cognitive abilities of aged APP/PS1-CCL17E/E mice were assessed. To test
whether the defiency of CCL17 in a mouse model of AD leads to an altered behavioral
phenotype in cognitive performance, aged APP/PS1-CCL17E/E, APP/PS1 as AD control,
and WT controls were analyzed in Morris water maze (MWM) paradigm, a commonly
used behavioral task for learning and memory [91, 131]. The MWM consists of two trials,
the acquisition phase and the probe trial. During the acquisition trial mice were trained
to find a hidden platform in a milky water bath (Fig.5.2.a), whereas the platform was
removed from the target quadrant T (Fig.5.2.c) during the probe trial to test the memory
strength. Statistical analysis revealed differences in both the acquisition task (genotype
effect: F2,161 = 32.13; p < 0.001) and in the probe trial (quadrant-genotype interaction:
F6,92 = 5.028; p < 0.001). In Fig.5.2.a, learning curves of APP/PS1-CCL17E/E, AP-
P/PS1, and WT are shown. On seven consecutive days WT mice showed an increasing
learning ability as given by a continuously decreasing curve for escape latency. As ex-
pected, APP/PS1 mice had a significantly increased escape latency during this task when
compared to WT. Interestingly, APP/PS1-CCL17E/E showed a significantly better per-
formance in this task when compared to APP/PS1 mice , and a similar learning ability
like WT mice. During the probe trial the memory strength is given by the time spent by
the mouse in the target quadrant. As shown in Fig.5.2.c, WT mice spent significant more
time in the target quadrant T than in the others (O = opposite, L = left, R = right).
APP/PS1-CCL17E/E mice showed a comparable memory strength like WT, whereas nor-
mal APP/PS1 mice had no preference to any quadrant. Differences in swim speed could
not be detected in all mouse groups, indicating differences in escape latency and time per
quadrant is not interfered by swim impairments (acquisition phase: F2,161 = 0.723; N.S.
and probe trial: F2,26 = 0.252, N.S.) (Fig.5.2.b, d).
Altogether, these data clearly show an WT-like behavioral phenotype and survival rate
of aged APP/PS1-CCL17E/E mice compared to their age-matched APP/PS1 controls.
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Figure 5.2: APP/PS1-CCL17E/E mice showed WT-like learning and memory performance in
a Morris water maze task
(a) Shown are learning curves of APP/PS1 (black circles), APP/PS1-CCL17E/E (black quad-
rants), and WT (open quadrants) mice during the acquisition trial. The curves present average
escape latencies ± SEM to the hidden platform on each of seven days of acquisition trials.
APP/PS1-CCL17E/E and WT mice exhibit a similar learning ability within 7 days, while
APP/PS1 mice had a significant higher escape latency. (b) Diagram shows the curves of swim
speed during the acquisition trial. (c) A schematic view of the Morris Water Maze pool vi-
sualizes representative swimming patterns of APP/PS1 (left), APP/PS1-CCL17E/E (middle)
and WT (right) mice in the water maze. The diagram shows the mean ± SEM of time spent
in each quadrant (T, target; L, left; O, opposite; and R, right) of the Morris water maze dur-
ing the probe trial. APP/PS1-CCL17E/E and WT spent significant more time in the target
quadrant than in the other quadrants. Both mouse strains showed a better performance than
APP/PS1 mice. (d) Diagram shows the mean ± SEM of swim speed during the probe trial.
The analysis of swim speed during acquisition trial (b) and probe trial (d) revealed no dif-
ferences in swimming performance in APP/PS1, APP/PS1-CCL17E/E , and WT mice. Data
analysis: (a), (b), (d): repeated measurement 2-way ANOVA with Bonferroni post-hoc, **p
< 0.01, and ***p < 0.001 for APP/PS1-CCL17E/E vs. APP/PS1, # p < 0.05, ##p < 0.01,
and ###p < 0.001 for WT vs. APP/PS1. (c): 1-way-ANOVA with Bonferroni post-hoc, ***p
< 0.001 for APP/PS1-CCL17E/E vs. APP/PS1, ###p < 0.001 for WT vs. APP/PS1. (n =
8-9 mice / group); (Fig.5.2: O¨nder Albayram)
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5.1.2 Reduced sAβ level in aged APP/PS1-CCL17E/E mice
The expression of the human amyloid precursor protein (APP) together with human
presenilin-1 (PSEN-1), part of the γ-secretase APP-cleaving complex, in mice (APP-
swe(K594N/M595L)/PS1dE9) results in a strong amyloid-beta plaque burden starting
at four to six months of age [17, 129]. To investigate whether CCL17 deficiency results
in an altered amyloid-beta load, the amount of soluble Aβ monomers and oligomers, as
well as deposited Aβ fibrils was assayed. First, the amount of extracellular deposits in
aged mice was determined to test whether the reduced cognitive decline is accompanied
by a reduced Aβ aggregation. For this, the percentage of occupied area and the size of
Thioflavine S-stained Aβ plaques in cortex and hippocampus (HC) was evaluated. In
Fig.5.3.a, representative immunofluorescence images of brain tissue slices of APP/PS1
(upper panel) and APP/PS1-CCL17E/E (lower panel) mice are shown. Equivalent plaque
size (Fig.5.3.b, right) and occupied area (Fig.5.3.b, left) were found in both groups.
Recent data suggested that soluble Aβ peptides are neurotoxic and the primary cause
of neuronal loss and cognitive decline rather than extracellular deposits [132]. Soluble Aβ
peptides were isolated by mild homogenization in sucrose buffer and a western blot analysis
was performed. In Fig.5.3.c, a representative picture of a western blot shows soluble
oligomeric and proto-fibrillic Aβ (oAβ) (top panel) as slightly diffuse bands due to different
oligomerization states. Monomeric Aβ is seen as sharp bands with a size of 3 kDa, whereas
dimeric Aβ shows relatively weak bands at 6 kDa. Interestingly, although a similar
expression of oAβ in middle-aged mice (lane 1-3 APP/PS1, 4-6 APP/PS1-CCL17E/E) was
found, the aged mice exhibit a marked reduction of soluble Aβ oligomers in APP/PS1-
CCL17E/E (lane 10-12) compared to APP/PS1 controls (lane 7-9). To exclude whether
the reduction of Aβ peptides is a result of reduced APP expression, western blotting of
sAPP in APP/PS1 and APP/PS1-CCL17E/E mice in both groups was assessed. However,
sAPP bands (62 kDa) present equivalent expression (Fig.5.3.c).
Enzymatic cleavage of APP by γ-secretase results in the production of several monomeric
Aβ isoforms with 36-43 amino acid residues. Aβ40 is the most common isoform produced
in the CNS, but Aβ42 is supposed to be the most toxic compound as it shows the high-
est aggregation tendency and is more abundant in plaques [9]. The amount of both Aβ
isoforms in the CNS of middle-aged and aged APP/PS1-CCL17E/E and APP/PS1 mice
were determined using ELISA. Since Aβ production and plaque deposition is reported to
start at around four to six months of age [17, 129], the amount of soluble Aβ40 and Aβ42
was analyzed in young mice as well. First, in order to control the isolation procedure
for protein analysis, the total amount of proteins in the CNS of young, middle-aged, and
aged mouse groups were determined by using BCA assay. The total protein content is
equivalent between all age groups, and between APP/PS1-CCL17E/E and age-matched
APP/PS1 mice (Fig.5.4).
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Figure 5.3: Equivalent plaque deposition, but reduced soluble Aβ oligomers in aged
APP/PS1-CCL17E/E mice
(a) Representative immunofluorescence images of brain tissue slices of APP/PS1-CCL17E/E
(lower) and APP/PS1 (upper) mice are shown (scale bar = 200 µm). (b) Diagrams show
mean ± SEM of area fraction (%) occupied by plaques (left) and mean plaque size (right)
in cortex and HC. APP/PS1-CCL17E/E (black bars) showed similar plaque deposition like
APP/PS1 (white bars) mice. (c) Western blot analysis of soluble Aβ oligomers (>188 kDa),
sAPP (66 kDa), and dimeric and monomeric Aβ (3 and 6 kDa) revealed reduced oAβ in aged
APP/PS1-CCL17E/E mice compared to age-matched APP/PS1 mice, but not in middle-aged
mice. Diagram shows mean ± SEM of oAβ/Actin ratio. Data analysis: Student’s t-test, ***p
< 0.001 for APP/PS1-CCL17E/E vs. APP/PS1. (n = 5 mice/group (b); 3 mice/group (c));
(Fig.5.3.c: Ilker Karaca)
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Figure 5.4: Equivalent total protein amount in the CNS of APP/PS1-CCL17E/E and
APP/PS1 mice
Diagram shows mean ± SEM of total protein concentration of one hemisphere of young,
middle-aged and aged APP/PS1-CCL17E/E and APP/PS1 mice. Data analysis: Student’s
t-test. (n = 7-14 APP/PS1, 11-13 APP/PS1-CCL17E/E)
Next, the determination of sAβ isoforms within the CNS and serum of APP/PS1-
CCL17E/E and APP/PS1 mice was carried out. Fig.5.5 shows diagrams of Aβ protein ex-
pression level in the serum, and in the CNS of young APP/PS1-CCL17E/E and APP/PS1
mice. Interestingly, in young mice enhanced levels of both, intracerebral Aβ40 (Fig.5.5.b)
and Aβ42 (Fig.5.5.c) isoforms respectively, were increased in APPPS1-CCL17E/E mice
compared to APP/PS1 controls. Furthermore, the serum Aβ concentration is reduced in
young APP/PS1-CCL17E/E mice compared to age-matched APP/PS1 mice (Fig.5.5.a).
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Figure 5.5: Increased Aβ levels in the CNS of young APP/PS1-CCL17E/E mice
(a-c) Diagrams show mean protein concentration ± SEM of serum Aβ42 (a) and intracerebral
sAβ40 (b) and sAβ42 (c) of young APP/PS1-CCL17E/E and APP/PS1 mice measured by
ELISA. Significant higher sAβ40 and sAβ42 levels, together with reduced serum Aβ42 were
found in young APP/PS1-CCL17E/E compared to age-matched APP/PS1 controls (a). Data
analysis: Student’s t-test, *p < 0.05, **p < 0.01 for APP/PS1-CCL17E/E vs. APP/PS1.
(Serum: n = 7-9 mice/group; CNS: 12-14 mice/group)
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However, as shown in Fig.5.6, in middle-aged mice equivalent levels of intracerebral
soluble Aβ40 and Aβ42 level, as well as serum Aβ42 concentrations were found.
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Figure 5.6: Equivalent Aβ in the CNS of middle-aged APP/PS1-CCL17E/E and APP/PS1
mice
(a-c) Diagrams show mean protein concentration ± SEM of serum Aβ42 (a) and intracerebral
sAβ40 (b) and sAβ42 (c) of middle-aged APP/PS1-CCL17E/E and APP/PS1 mice measured
by ELISA. In middle-aged mice all Aβ levels were found to be equivalent between both mouse
groups. Data analysis: Student’s t-test. (Serum: n = 11-12 mice/group; CNS: 11-12 mice/-
group)
Fig.5.7 shows diagrams of Aβ protein expression level in the serum and in the CNS of
aged APP/PS1-CCL17E/E and APP/PS1 mice. WT samples were assayed as controls.
Although the measurement of sAβ40 in the CNS of WT mice revealed a high background,
Aβ42 levels in the CNS and serum of WT mice were at a low background level as expected
(Fig.5.7). Similar to the results of middle-aged mice, serum Aβ42 levels and intracerebral
Aβ40 levels were found to be equivalent in aged APP/PS1-CCL17E/E and APP/PS1 mice
(Fig.5.7.a, b). However, the sAβ42 level in the CNS of aged APP/PS1-CCL17E/E mice
was significantly reduced compared to APP/PS1 mice (Fig.5.7.c).
Altogether, measurement of Aβ42 levels in young, middle-aged and aged APP/PS1-
CCL17E/E and APP/PS1 mice revealed an increase of Aβ concentration from < 20 pg/ml
in the young mouse group to ∼ 100 pg/ml in the aged mouse group (age effect: F2,2=
114,444; p <0.01). Furthermore, intracerebral sAβ40 levels rise from < 400 pg/ml to
∼ 1500 pg/ml. Interestingly, in APP/PS1 mice the intracerebral sAβ42 concentration
showed a strong increase from < 3000 pg/ml in young mice to ∼ 6000 pg/ml in aged
mice (F2,30= 6.232; p <0.01), while in contrast the intracerebral sAβ42 concentrations of
APP/PS1-CCL17E/E mice in all three age groups were found to be ∼ 4000 pg/ml (F2,33=
0.8555; N.S.).
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Figure 5.7: Reduced sAβ42 in the CNS of aged APP/PS1-CCL17E/E mice
(a-c) Diagrams show mean protein concentration ± SEM of serum Aβ42 (a) and intracerebral
sAβ40 (b) and sAβ42 (c) of aged APP/PS1-CCL17E/E (black bars), APP/PS1 (white bars),
and WT (light grey bars) mice measured by ELISA. While serum Aβ42 and intracerebral
sAβ40 level were found to be equivalent in aged mice, sAβ42 level was significant reduced in
APP/PS1-CCL17E/E mice compared to APP/PS1 controls. WT mice show small amounts of
Aβ40 and Aβ42 levels (c). Data analysis: Student’s t-test, *p < 0.05, **p < 0.01 for APP/PS1-
CCL17E/E vs. APP/PS1. (Serum: n = 6-10 mice/group, 5 WT; CNS: 7-11 mice/group, 5
WT)
5.1.3 Reduced NeuN+ neurons in the hippocampus of APP/PS1
mice, but not in APP/PS1-CCL17E/E mice
The overproduction of Aβ peptides and plaque deposition is often related to cognitive
impairment and neuronal loss [43, 130, 133]. In order to evaluate the neuronal integrity
of hippocampal neurons, a neuronal nuclei (NeuN) immunofluorescence staining for ma-
ture neurons [133, 134] was assessed in brain tissue slices of aged APP/PS1-CCL17E/E,
APP/PS1, and WT mice. In Fig.5.8, representative immunofluorescence images of the
hippocampal CA3 region of brain tissue slices of WT (left panel), APP/PS1 (middle),
and APP/PS1-CCL17E/E (right) mice are shown. APP/PS1-CCL17E/E exhibit a NeuN
staining pattern comparable to WT mice. In contrast, APP/PS1 mice showed a marked
reduction in NeuN+ neurons, indicating a loss of mature neurons in the hippocampus.
Quantification of NeuN immunoreactive cells as area fraction (% of area) revealed a sig-
nificant reduction of NeuN staining pattern in the hippocampus of brain tissue slices
of aged APP/PS1 mice compared to age-matched APP/PS1-CCL17E/E and WT mice.
Survival of neurons is multifactory-dependent, one major component discussed to play
a potential role in AD is the brain-derived neurotrophic factor BDNF [9, 123]. The
expression level of bdnf mRNA in the hippocampus of aged APP/PS1-CCL17E/E mice
was assayed using qRT-PCR. Equivalent bdnf level was found in the HC of APP/PS1-
CCL17E/E mice compared to WT and CCL17E/E control, whereas the bdnf expression is
increased in APP/PS1 mice (Fig.5.8.c).
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Figure 5.8: Reduced NeuN immunoreactivity in the hippocampus of APP/PS1 mice, but not
in APP/PS1-CCL17E/E mice
(a) Representative sagittal sections of hippocampal CA3 region of WT (left), APP/PS1 (mid-
dle), and APP/PS1-CCL17E/E (right) (scale bar = 50 µm). (b) Diagram shows mean area
fraction ± SEM of NeuN immunoreactive tissue slices. APP/PS1-CCL17E/E (black bar) and
WT (light grey bar) exhibit a similar NeuN staining pattern in contrast to APP/PS1 mice
(white bar), which showed a marked reduction of NeuN immunoreactivity. (c) qRT-PCR
analysis of bdnf mRNA in the hippocampus of aged APP/PS1-CCL17E/E (black bar), AP-
P/PS1 (white bar), CCL17E/E (dark grey bar), and WT (light grey bar) mice. Diagram shows
mean ± SEM. Data analysis: 1-way-ANOVA and Student’s t-test, *p < 0.05 for APP/PS1-
CCL17E/E vs. APP/PS1, and #p < 0.05 for APP/PS1 vs. WT. (b: n = 3-4 mice/group, c:
4-6 non-tg, 8-9 tg); (Fig.5.8.a, b: Christina Mu¨ller)
These data show a reduced soluble Aβ concentration, but not of insoluble Thioflavin-
positive plaques, within the CNS of aged APP/PS1-CCL17E/E mice, which is accompa-
nied by a reduced loss of mature neurons in the hippocampal region.
40
5 Results
5.1.4 Analysis of APP/PS1-CCL17E/+ reporter mice
Investigation of eGFP expressing cells in the periphery and the CNS of
APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
Alferink et al. showed that CCL17 is mainly expressed by mature DCs in various lym-
phoid and non-lymphoid organs using a CCL17 reporter mouse model [101]. In this
study an eGFP (enhanced green fluorescent product) cassette was inserted via homolo-
gous recombination into the murine ccl17 locus under the control of the ccl17 promotor.
After blastocyste injection chimeric mice were backcrossed to a C57BL/6 background and
heterozygous CCL17E/+ mice expressed wildetype CCL17 and eGFP reporter protein.
Homozygous CCL17E/E mice, carrying the eGFP construct on both alleles, are deficient
for murine CCL17. CCL17E/+ and CCL17E/E cells are visualized by their green fluo-
rescence. The dominant cellular producers of CCL17 are CD11c+ DCs. eGFP+ DCs
can be identified in the LN in CCL17E/+ heterozygous mice under physiological and in-
flammatory conditions [101], and in spleen only after NKT (natural killer T) cell ligand
induction [113]. To investigate whether the amount of CCL17+ DCs is altered in the pe-
riphery of APP/PS1-CCL17E/+ due to APP/PS1 expression, flow cytometric analysis of
green-fluorescent DCs in LNcerv, LNax,mes, spleen, and blood was performed. Additionally,
it was asked whether eGFP+ cells can be detected in the CNS of APP/PS1-CCL17E/+
mice or their healthy controls.
However, in LNax,mes and LNcerv of APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
equivalent levels of eGFP+CD11c+ cells were found (Fig.5.9.b, c). Analysis of PBMC
and spleen revealed relatively low percentages of eGFP+CD11c+ cells (Fig.5.9.c). In the
spleens of these mice less than 1 % of isolated cells present eGFP expression, whereas in
blood and in brain tissue eGFP+ cells could not be detected. This result fits to previous
observations in which the investigation of brain tissue slices of APP/PS1-CCL17E/+ re-
vealed no eGFP+ cells, although green-fluorescent cells could be found in LN of APP/PS1-
CCL17E/+ mice [127].
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Figure 5.9: Equivalent percentages of eGFP+DCs in LNax,mes, LNcerv, and spleen of
APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
(a) Representative dot plots of CD11c+eGFP+ cells isolated from LNcerv of APP/PS1-
CCL17E/+ (right) and CCL17E/+ (left) mice. Blue gates: CD11c+eGFP+ cells. Numbers
are frequencies (in %). (b-d) Equivalent percentages of eGFP+CD11c+ cells in LNax,mes (b),
LNcerv (c), and spleen (d) in APP/PS1-CCL17E/+ and CCL17E/+ mice. Diagrams show
mean ± SEM. Data analysis: Student’s t-test. (n = 3-4 mice/group)
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Quantification of peripheral myeloid and lymphoid cells in APP/PS1-CCL17E/+
and CCL17E/+ reporter mice
Several studies showed an AD-related alteration of peripheral biomarkers or a modulated
Aβ reactivity of peripheral immune cells in humans [121, 122, 123, 124]. To investigate
whether the overexpression of APP/PS1 in a mouse model of AD leads to an alteration in
the numbers of peripheral immune cells, the analysis of heterozygous APP/PS1-CCL17E/+
reporter mice was conducted.
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Figure 5.10: Equivalent percentages of LN-derived CD11b+, CD11c+, and TCR+ cells in
APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
(a-d) Diagrams show mean ± SEM of equivalent total cell numbers (a) and percentages of
CD11b+ (b), CD11c+ (c), and TCR+ cells (d) isolated from pooled axillary, inguinal, and
mesenterial lymph nodes of APP/PS1-CCL17E/+ (black bars) and CCL17E/+ (white bars)
mice. (e) Representative dot plots of LN-derived TCR+ T cells. Numbers in blue quad-
rant gates are the frequencies of events (in %). Data analysis: Student’s t-test. (n = 5
mice/group)
First, cells from pooled axillary, inguinal, and mesenterial lymph nodes (LNax,mes) and
from the spleen of 10-12 months-old APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
were isolated and the amount of myeloid and lymphoid cells were determined using flow
cytometry. For this, total cell numbers were counted and cells were stained for CD11b
(monocytes / macrophages), CD11c (dendritic cells) and T-cell receptor TCR (T cells)
surface expression.
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As shown in Fig.5.10.a, cell counting revealed equivalent total cell numbers in lymph
nodes of APP/PS1-CCL17E/+ and CCL17E/+ reporter mice. Flow cytometric analysis
of CD11b+ (Fig.5.10.b), CD11c+ (Fig.5.10.c), and TCR+ (Fig.5.10.d) LN-derived cells
revealed also no differences between the two mouse groups. In Fig.5.10.e, representative
dot plots of TCR+ cells (SSC vs. TCR PerCP-Cy5.5) isolated from LNax,mes of APP/PS1-
CCL17E/+ (right) and CCL17E/+ (left) are depicted. Furthermore, flow cytometric anal-
ysis of splenic cells of APP/PS1-CCL17E/+ and CCL17E/+ reporter mice revealed equiva-
lent total cell numbers (Fig.5.11.a), CD11b+ (Fig.5.11.b), CD11c+ (Fig.5.11.c), and TCR+
(Fig.5.11.d) cells.
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Figure 5.11: Equivalent percentages of CD11b+, CD11c+ and TCR+ cells in the spleen of
APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
(a-d) APP/PS1-CCL17E/+ and CCL17E/+ mice present equivalent total cell numbers (a)
and percentages of CD11b+ (b), CD11c+ (c), and TCR+ cells (d). Diagrams show mean ±
SEM. Data analysis: Student’s t-test. (n = 5 mice/group)
It was reported that drainage of Aβ from the CNS to cervical lymph nodes (LNcerv)
can occur [125, 126]. Since own data showed that CD11c+ DCs are able to phagocy-
tose Aβ peptides in vitro [127], the amount of CD11c+ DCs in cervical LN and blood
(peripheral blood mononuclear cells (PBMC)) of APP/PS1-CCL17E/+ mice was deter-
mined. In Fig.5.12.a, representative dot plots of LNcerv-derived CD11c+ cells (SSC vs.
CD11c AF647) are shown. However, the determination of total cell numbers and CD11c+
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cells revealed no differences between APP/PS1-CCL17E/+ and CCL17E/+ reporter mice
neither in LNcerv (Fig.5.12.b) nor in PBMC (Fig.5.12.c).
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Figure 5.12: Equivalent total cell numbers and CD11c+ cells in LNcerv of APP/PS1-CCL17E/+
and CCL17E/+
(a) Representative dot plots of CD11c+ cells isolated from LNcerv of APP/PS1-CCL17E/+
(right) and CCL17E/+ (left) mice. (b-c) Diagrams show mean ± SEM of total cell numbers
and percentages of CD11c+ cells of LNcerv (b) and PBMC (c). Data analysis: Student’s
t-test. (n = 5 mice/group)
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Characterization of intracerebral leukocytes of APP/PS1-CCL17E/+ and CCL17E/+
reporter mice
To determine the amount of invading and resident mononuclear cells in the CNS of
APP/PS1-CCL17E/+ reporter mice, isolated intracerebral leukocytes (ICL) from the CNS
were analyzed by flow cytometry using CD11b and CD45 double staining. CD11b is ex-
pressed by several cell types within the CNS such as invading monocytes / macrophages
and CNS-resident microglial cells. In contrast, CD45 is expressed by CNS-infiltrating
cells such as lymphocytes and monocytes / macrophages. In Fig.5.13.b, a representative
dot plot of CD45+ CD11b+ cells, pre-gated for life cells, is given.
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Figure 5.13: Equivalent numbers of intracerebral leukocytes in APP/PS1-CCL17E/+ and
CCL17E/+ reporter mice
(a) Diagram shows mean ± SEM of total cell numbers of intracerebral leukocytes (ICL) of
APP/PS1-CCL17E/+ and CCL17E/+ mice. (b) Representative dot plot of CD45+CD11b+
ICL. Gates are indicated in blue ovals. Numbers are frequencies of events (in %). (c-e)
Flow cytometric analysis of ICL of APP/PS1-CCL17E/+ and CCL17E/+ mice revealed no
differences of lymphocyte (c), monocyte / macrophage (d), and microglia (e) populations.
Diagrams show mean ± SEM. Data analysis: Student’s t-test. (n = 3-4 mice/group)
As shown by gates (blue ovals) three different main cellular populations can be dis-
tinguished: (1) Lymphocytes as CD45highCD11b− cells, (2) macrophages as CD45high
CD11bhigh cells, and (3) microglia as CD45lowCD11bhigh cells. The numbers within the
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gates are representative percentaged distribution of the cells. The analysis of intrac-
erebral lymphocytes, macrophages, and microglial cells revealed no differences between
APP/PS1-CCL17E/+ and CCL17E/+ mice (Fig.5.13.c, d, and e).
In addition, the activation status of ICL by CD40 expression was assessed. Enhanced
CD40 levels by microglia are linked to chronic inflammation as it occurs in AD progression
[128]. Flow cytometric analysis of CD40 expression by CD45/CD11b pre-gated lympho-
cytes, monocytes / macrophages, and microglia in the CNS of APP/PS1-CCL17E/+ and
CCL17E/+ reporter mice revealed an increase of mean fluorescence intensity (MFI) of
CD40 by microglia and macrophages, but not by lymphocytes isolated from the CNS of
APP/PS1-CCL17E/+ mice compared to healthy controls, as shown in Fig.5.14. Further-
more, lymphocytes possess the lowest CD40 geometric MFI in both mouse strains, while
microglia have the highest geometric MFI.
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Figure 5.14: Increased CD40 expression on macrophages and microglia in the CNS of
APP/PS1-CCL17E/+ reporter mice
Enhanced geometric mean fluorescence intensity (MFIgeo) of CD40+ microglia and
macrophages in the CNS of APP/PS1-CCL17E/+ mice compared to CCL17E/+ controls.
Lymphocytes showed the lowest CD40 MFIgeo. Diagram shows mean ± SEM. Data analysis:
Student’s t-test; **p <0.01. (n = 3-4 mice/group)
Altogether, no alteration in the numbers of myeloid and lymphoid cells in periph-
eral and brain tissue due to APP/PS1 transgene expression could be detected in 10-12
months-old APP/PS1-CCL17E/+ mice compared to CCL17E/+ mice. However, microglia
and macrophages isolated from brains of APP/PS1-CCL17E/+ mice revealed a higher ac-
tivation status as indicated by CD40 expression compared to their CCL17E/+ controls.
Interestingly, eGFP expressing CD11c+ cells were equivalent in spleen and LN, and not
found in the brain or blood in both mouse strains.
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5.1.5 Characterization of inflammatory CNS responses
in APP/PS1-CCL17E/E mice
Neuroinflammation is characterized by the activation and proliferation of astrocytes (as-
trocytosis) and microglial cells (microgliosis), which is accompanied by morphological
changes and altered gene transcription [28]. Astrocytosis is marked by an extensive up-
regulation of the intermediate filament protein GFAP (glial fibrillary acidic protein) and
in context of AD, GFAP expression is correlated with Aβ accumulation [135]. Microglio-
sis in turn, is characterized by an increased CD11b expression by microglial cells upon
activation [136]. To assess the inflammatory profile in the CNS of APP/PS1-CCL17E/E
mice during robust plaque progression, the amount of GFAP+ and CD11b+ cells was
determined in aged mice within cortex and hippocampus (HC) by immunofluorescence
(Fig.5.15).
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Figure 5.15: Enhanced GFAP expression in aged APP/PS1-CCL17E/E and APP/PS1 mice
(a) Representative images of hippocampal CA1 region of GFAP immunoreactive brain slices
of APP/PS1-CCL17E/E , APP/PS1, and WT mice (scale bar = 50 µm). (b) Quantitative
analysis of cortex and HC revealed increased number GFAP+ cells in APP/PS1-CCL17E/E
(black bar) and APP/PS1 (white bar) compared to WT controls (light grey bar). Diagram
shows mean area fraction ± SEM. Data analysis: 1-way-ANOVA with Bonferroni post-hoc,
*p < 0.05 (APP/PS1-CCL17E/E vs. APP/PS1), #p < 0.05, ##p < 0.01, ###p < 0.001 (tg
vs. WT). (n = 3 / group); (Fig.5.15: Christina Mu¨ller)
Representative images of GFAP and CD11b staining in CA1 region of HC are shown
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in Fig.5.15.a, b. A marked increase of GFAP immunoreactive cells were found in the
cortex and HC of APP/PS1 mice compared to WT mice. However, APP/PS1-CCL17E/E
mice showed similar GFAP staining pattern like APP/PS1 mice (Fig.5.15.a). In contrast,
the quantitative analysis of CD11b immunoreactive cells in brain tissue slices revealed
an increase of CD11b immunoreactive cells in the cortex and HC of aged APP/PS1-
CCL17E/E mice compared to APP/PS1 and WT mice (Fig.5.15.b).
Next, CD11b expression within the CNS of young, middle-aged, and aged mice were
assessed to investigate whether there is an age-dependent alteration of microgliosis in
the CNS of APP/PS1-CCL17E/E mice. Therefore, ICL of young, middle-aged, and aged
APP/PS1-CCL17E/E and APP/PS1 mice were isolated and flow cytometric analysis of
CD11b+ cells was performed.
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Figure 5.16: Equivalent CD11b expression in young, but enhanced expression in the CNS of
aged APP/PS1-CCL17E/E mice
(a-c) Diagrams show mean ± SEM of total cell numbers (left) and numbers of CD11b+ cells
(right) in the CNS of young (a), middle-aged (b), and aged (c) APP/PS1-CCL17E/E (black
bars) and APP/PS1 (white bars) mice. Total cell numbers and numbers of CD11b+ cells are
equivalent in young and middle-aged mice, but increased in aged APP/PS1-CCL17E/E mice.
(c) Pooled CNS of WT (light grey bar) and CCL17E/E (dark grey bar) mice were used as
non-tg controls. Total cell numbers and percentaged CD11b+ cells were decreased in non-tg
mice compared to both gt mouse strains. Data analysis: Student’s t-test or 1-way-ANOVA
with Bonferroni post-hoc, **p < 0.01, ***p < 0.001 (APP/PS1 vs. APP/PS1-CCL17E/E),
###p < 0.001 (tg vs. WT). (n = 3-4 mice/group)
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peptides and plaques [43, 70]. One key marker characterizing these cells, is the expression
of the chemokine receptor CCR2 and the monocytic marker Ly6C [73]. As enhanced
immigrating macrophages were found in the CNS of aged APP/PS1-CCL17E/E mice, it
was investigated whether these cells express CCR2 and Ly6C. First, the expression levels
of ccr2 mRNA in the cortex of young, middle-aged, and aged APP/PS1-CCL17E/E mice
were analyzed. Indeed, significant higher ccr2 expression levels were found in the cortex
of young (Fig.5.18.a) and middle-aged (Fig.5.18.b) APP/PS1-CCL17E/E mice compared
to APP/PS1 controls. However, ccr2 mRNA expression analysis of aged mice revealed
no differences (Fig.5.18.c).
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Figure 5.18: Enhanced ccr2 mRNA in the CNS of APP/PS1-CCL17E/E mice
(a-c) qRT-PCR analysis of ccr2 mRNA in the cortex of APP/PS1-CCL17E/E (black bar)
and APP/PS1 (white bar) mice. Enhanced ccr2 mRNA levels were found in young (a) and
middle-aged (b) APP/PS1-CCL17E/E mice compared to APP/PS1 mice, but not in aged
mice (c). Data analysis: Student’s t-test, **p <0.01, ***p < 0.001. (n = 8-10 mice/group)
Next, in order to identify the CCR2+ cells in the CNS of APP/PS1-CCL17E/E and
APP/PS1 mice, flow cytometric analysis were assessed on ICL. Interestingly, in line with
mRNA data of the younger mice, but in contrast to the aged mice, a significant higher
number of CCR2+ cells were found in the CNS of APP/PS1-CCL17E/E mice compared to
APP/PS1 mice (Fig.5.19.a). In contrast, WT and CCL17E/E mice exhibit low numbers
of CCR2+ cells. Moreover, as shown in Fig.5.19.b, CCR2 is most expressed by invad-
ing macrophages, at a lower level by microglial cells, and nearly absent on lymphocytes.
Further, CCR2 expression is significant higher in both AD mouse groups than in healthy
control groups. Representative CCR2 histograms of WT, CCL17E/E, APP/PS1, and
APP/PS1-CCL17E/E lymphocytes (light grey solid curve), macrophages (black line), and
microglia (grey line) are shown in Fig.5.19.c. Furthermore, a significantly higher number
of Ly6ChighCCR2+ macrophages was found in the CNS of APP/PS1-CCL17E/E mice com-
pared to APP/PS1 mice (Fig.5.20.a, b). Interestingly, the Ly6ChighCCR2+ macrophage
population is absent in non-tg mice, indicating an immigration of peripheral macrophages
due to Aβ overexpression in both APP/PS1 tg mouse groups (Fig.5.20.a, b).
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SampleName GateName Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56.1 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Monocytes 29.9 53.6 99.4
05jan2012_Ly6C CNS_14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS_14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS_14mths_4223.fcs Lympho-,Monocytes 4.16 44 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_4211.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_4213.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_4214.fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS_14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fcs Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fcs Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrophages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrophages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrophages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 84 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 114 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 118 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
APP/PS1-CCL17E/E:
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WT:
05jan2012_Ly6C CNS 14mths Layout: CCR2+ populations histogramms
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SampleName GateN me Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56.1 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Monocytes 29.9 53.6 99.4
05jan2012_Ly6C CNS_14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS_14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS_14mths_422 .fcs Lympho-,Monocytes 4.16 44 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_42 1.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_42 3.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_42 4.fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS_14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fcs Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fcs Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrophages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrophages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrophages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 84 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 114 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 118 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
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SampleName GateName Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56.1 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Monocytes 29.9 53.6 99.4
05jan2012_Ly6C CNS_14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS_14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS_14mths_4223.fcs Lympho-,Monocytes 4.16 44 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_4211.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_4213.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_4214.fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS_14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fcs Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fcs Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrophages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrophages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrophages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 8 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 1 4 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 11 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
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SampleName GateName Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56.1 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Monocytes 29.9 53.6 99.4
05jan2012_Ly6C CNS 14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS 14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS 14mths_4223.fcs Lympho-,Monocytes 4.16 44 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_4211.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_4213.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_4214.fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS_14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fcs Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fcs Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrophages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrophages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrophages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 84 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 114 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 118 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
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SampleName GateName Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56. 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Monocytes 29.9 53.6 99.4
05jan2012_Ly6C CNS_14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS_14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS_14mths_4223.fcs Lympho-,Monocytes 4.16 4 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_4211.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_4213.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_4214.fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS_14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fcs Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fcs Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrop ages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrop ages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrop ages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 84 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 114 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 118 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
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SampleName GateName Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56.1 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Mon cytes 29.9 53.6 99.4
05jan2012_Ly6C CNS_14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS_14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS_14mths_4223.fcs Lympho-,Monocytes 4.16 44 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_4211.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_4213.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_4214.fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS_14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fcs Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fcs Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrophages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrophages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrophages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 84 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 114 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 118 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
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SampleName GateName Freq. of Parent CCR2 Ly6C
05jan2012_Ly6C CNS_14mths_WT 1.fcs Lympho-,Monocytes 11 52.4 121
05jan2012_Ly6C CNS_14mths_WT 2.fcs Lympho-,Monocytes 11.4 56.6 130
05jan2012_Ly6C CNS_14mths_WT 3.fcs Lympho-,Monocytes 11 56. 131
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Lympho-,Monocytes 8.45 52.8 158
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Lympho-,Monocytes 8.27 46.7 134
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Lympho-,Monocytes 8.34 46.1 126
05jan2012_Ly6C CNS_14mths_4193.fcs Lympho-,Monocytes 29.9 53.6 99.4
05jan2012_Ly6C CNS_14mths_4198.fcs Lympho-,Monocytes 17.9 51.6 110
05jan2012_Ly6C CNS_14mths_4220.fcs Lympho-,Monocytes 12.4 45.9 123
05jan2012_Ly6C CNS_14mths_4223.fcs Lympho-,Monocytes 4.16 4 112
05jan2012_Ly6C CNS_14mths_4201.fcs Lympho-,Monocytes 4.91 52.8 138
05jan2012_Ly6C CNS_14mths_4211.fcs Lympho-,Monocytes 3.88 44.7 104
05jan2012_Ly6C CNS_14mths_42 3.fcs Lympho-,Monocytes 4.63 46.8 108
05jan2012_Ly6C CNS_14mths_42 .fcs Lympho-,Monocytes 4.53 44.4 148
05jan2012_Ly6C CNS 14mths_WT 1.fcs Macrophages 9.96 100 363
05jan2012_Ly6C CNS_14mths_WT 2.fc Macrophages 10.6 101 362
05jan2012_Ly6C CNS_14mths_WT 3.fc Macrophages 10.3 100 373
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Macrop ages 10.9 75.4 364
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Macrop ages 11.1 75.6 370
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Macrop ages 11.6 84.7 430
05jan2012_Ly6C CNS_14mths_4193.fcs Macrophages 31.3 150 724
05jan2012_Ly6C CNS_14mths_4198.fcs Macrophages 27.1 166 717
05jan2012_Ly6C CNS_14mths_4220.fcs Macrophages 26.9 175 752
05jan2012_Ly6C CNS_14mths_4223.fcs Macrophages 12.8 191 896
05jan2012_Ly6C CNS_14mths_4201.fcs Macrophages 30.8 216 748
05jan2012_Ly6C CNS_14mths_4211.fcs Macrophages 14.5 177 651
05jan2012_Ly6C CNS_14mths_4213.fcs Macrophages 18.1 186 792
05jan2012_Ly6C CNS_14mths_4214.fcs Macrophages 24.4 172 942
05jan2012_Ly6C CNS_14mths_WT 1.fcs Microglia 21.5 86.9 1446
05jan2012_Ly6C CNS_14mths_WT 2.fcs Microglia 21.7 91 1490
05jan2012_Ly6C CNS_14mths_WT 3.fcs Microglia 21.4 90.4 1495
05jan2012_Ly6C CNS_14mths_TARC 1.fcs Microglia 18.1 87 1442
05jan2012_Ly6C CNS_14mths_TARC 2.fcs Microglia 18 84 1349
05jan2012_Ly6C CNS_14mths_TARC 3.fcs Microglia 26.9 139 1319
05jan2012_Ly6C CNS_14mths_4193.fcs Microglia 11.3 125 1751
05jan2012_Ly6C CNS_14mths_4198.fcs Microglia 8.86 131 1847
05jan2012_Ly6C CNS_14mths_4220.fcs Microglia 15.3 115 1832
05jan2012_Ly6C CNS_14mths_4223.fcs Microglia 12.6 114 2014
05jan2012_Ly6C CNS_14mths_4201.fcs Microglia 15.1 176 1924
05jan2012_Ly6C CNS_14mths_4211.fcs Microglia 28.1 103 1780
05jan2012_Ly6C CNS_14mths_4213.fcs Microglia 21.8 118 1965
05jan2012_Ly6C CNS_14mths_4214.fcs Microglia 20.8 120 1899
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Figure 5.19: Increased numbers of CCR2+ cells in the CNS of aged APP/PS1-CCL17E/E mice
(a) Flow cytometric analysis of CCR2+ cells in the CNS of aged APP/PS1-CCL17E/E (black
bar), APP/PS1 (white bar), WT (light grey bar), and CCL17E/E (dark grey bar) mice.
Diagram shows mean ± SEM. (b) Geometric mean fluoresence intensit (MFIgeo) of CCR2+
macrop ages is increased in APP/PS1-CCL 7E/E and APP/PS1 mice compared to non-tg
mice. Diagram shows mean MFIgeo ± SEM. (c) Representative CCR2 histogram overlays of
lymphocytes (light grey solid curve), macrophages (black line), and microglia (grey line) are
shown of WT, CCL17E/E , APP/PS1, and APP/PS1-CCL17E/E mice. % of Max = number
of events normalized according to the FlowJo algorithms. Dat analysis: 1-way-ANOVA
with Bonferroni post-hoc, **p <0.01, ***p < 0.001 (APP/PS1 vs. APP/PS1-CCL17E/E);
##p <0.01, ###p < 0.001 (tg vs. WT). (n = 3-4 mice/group)
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Figure 5.20: Enhanced Ly6ChighCCR2+ cell immigration into the CNS of APP/PS1-
CCL17E/E mice
(a) Representative dot plots of Ly6ChighCCR2+ macrophages (blue gates) (CD45+CD11b+
pre-gated) are shown of WT, CCL17E/E , APP/PS1, and APP/PS1-CCL17E/E mice. (b)
Significant higher numbers of Ly6ChighCCR2+ macrophages were found in the CNS of aged
APP/PS1-CCL17E/E compared to APP/PS1. Diagrams show mean ± SEM. (c, d) Equiva-
lent levels of CD11b+ and Ly6ChighCCR2+ PBMC of aged APP/PS1-CCL17E/E and AP-
P/PS1 mice. Diagrams show mean ± SEM . (e) Diagram shows mean ± SEM of CCL2
protein level in the CNS of young, middle-aged, and aged APP/PS1-CCL17E/E and AP-
P/PS1 mice. CCL2 concentrations showed an age-dependent increase, but equivalent levels
between age-matched mouse groups. Data analysis: Student’s t-test and 1-way-ANOVA with
Bonferroni post-hoc, **p <0.01, ***p < 0.001 (APP/PS1 vs. APP/PS1-CCL17E/E); ###p
< 0.001 (tg vs. WT). (a-d: n = 3-4 mice/group; e: n = 7-9 mice/group)
Next, the amount of Ly6Chigh CCR2+ monocytes in the peripheral blood of aged
APP/PS1-CCL17E/E mice was assayed, to test whether an increase of intracerebral
Ly6ChighCCR2+ macrophages is accompanied by an increase of peripheral blood Ly6Chigh
CCR2+ monocytes. However, the amount of CD11b+ PBMC and Ly6ChighCCR2+ mono-
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cytes is equivalent in both mouse groups (Fig.5.20.c, d). To determine, whether increased
invasion of peripheral Ly6ChighCCR2+ macrophage is related to an increase of intrac-
erebral CCR2 ligand CCL2 expression, CCL2 concentration was measured in the CNS
of young, middle-aged, and aged APP/PS1-CCL17E/E mice. However, although an age-
dependent increase of intracerebral CCL2 level could be detected, differences in CCL2
expression between APP/PS1-CCL17E/E and APP/PS1 mice were not found (Fig.5.20.e).
Altogether, the analysis of intracerebral leukocytes of aged APP/PS1-CCL17E/E mice
revealed an increase of CNS-resident microglia cells and a higher infiltration of peripheral
monocytes / macrophages, which express high levels of Ly6C and CCR2 cell surface
markers. Interestingly, this is not accompanied by an increase of CCL2 within the CNS
of these mice. In addition, the amount of Ly6ChighCCR2+ PBMC were equivalent in
APP/PS1-CCL17E/E and APP/PS1 mice.
5.1.7 Analysis of CCL17 (eGFP) expression in APP/PS1 transgenic
mice
Recently, ccl17 mRNA was found to be overexpressed in the frontal cortex of APPswe
mice after intranasal Tat exposure modeling cerebral HIV-1 infection, suggesting a pos-
sible role of CCL17 during neuroinflammation and -degeneration [116]. However, similar
to the heterozygous mice intracerebral localized eGFP+ cells could not be detected by
either confocal microscopy (data not shown) or flow cytometry (Fig.5.21) in APP/PS1-
CCL17E/E mice and CCL17E/E controls. Representative dot plots of CD11b and eGFP
(Fig.5.21.a), and representative eGFP histograms of intracerebral macrophages and mi-
croglial cells (Fig.5.21.b) are shown. To investigate, whether CCL17 expression is altered
due to APP/PS1 expression in the CNS of tg mice, the ccl17 mRNA level in the hip-
pocampus of aged APP/PS1 and WT mice was determined. Indeed, CCL17 expression
is upregulated in APP/PS1 mice compared to healthy WT mice (Fig.5.22.a). To un-
ravel the cellular source of intracerebral CCL17, ICL of aged APP/PS1 and WT mice
were isolated and CCL17 expression was evaluated by qRT-PCR. As seen in Fig.5.22.b,
it was found that adult microglia isolated from aged APP/PS1 and WT mice express
ccl17 mRNA. mRNA analysis of cortical tissue of CCL17E/E mice exhibit no ccl17 ex-
pression, in contrast to WT mice, indicating no false-positive signal for RT-PCR analysis
(Fig.5.22.c).
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Figure 5.2 : eGFP+ cells are absent in the CNS of APP/PS1-CCL17E/E and CCL 7E/E mice
(a) Representative dot plots of CD11b eGFP expression of I L of aged APP/PS1-CCL 7E/E
mice (right) and CCL17E/E mice (middle). ICL of aged APP/PS1 mice (left) served as eGFP
negative control. (b) Representative eGFP histograms of CD45+CD11b+ gated microglia
(left) and macrophages (right) of APP/PS1-CCL17E/E mice (black line) and CCL17E/E
mice (black dashed line). APP/PS1 mice (light grey solid curve) served as eGFP negative
control.
The cognate receptor CCR4 is predominantly found on Th2 cells, but also on DCs,
macrophages, NK cells and other cell types [137]. In addition, CCR4 expression was
found in human astrocytes and microglial cells [138] and rat hippocampal neurons [139].
To investigate whether mouse microglia also express CCR4, primary neonatal microglial
cells, isolated from WT and CCL17E/E mice were analyzed for ccr4 mRNA without
and after LPS stimulation. RNA from LPS stimulated BM-derived WT DCs served as
positive control. LPS stimulated microglia present an extensive upregulation of ccr4
mRNA compared to unstimulated controls, although CCR4 expression was much more
higher in BM-differentiated DCs (Fig.5.22.b).
Beside CCL17, the other known ligand of CCR4 is CCL22. The analysis of ccl22 mRNA
in the hippocampus of APP/PS1-CCL17E/E and CCL17E/E mice revealed an enhanced
expression of CCL22 compared to APP/PS1 and WT mice. Interestingly, the CCL22
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expression is not changed by APP/PS1 transgene expression (Fig.5.23.a).
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Figure 5.22: Microglia are a potential source for elevated CCL17 expression in APP/PS1
mice
(a) Enhanced ccl17 mRNA expression level in the hippocampus of APP/PS1 mice (grey
bar) compared to WT mice (white bar). (b) Isolated ICL of aged APP/PS1 and WT express
ccl17 mRNA. (c) Cortex of CCL17E/E mice did not show ccl17 mRNA expression in contrast
to cortical tissue of WT mice (c). Diagrams show mean relative expression ± SEM. Data
analysis: Student’s t-test; *p <0.05. (n = 4-9 mice/group)
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Figure 5.23: CCR4 is expressed by neonatale microglia after LPS stimulation
(a) Microglia of WT (white bar) and CCL17E/E (black bar) express ccr4 mRNA after LPS
stimulation, but to a lesser extent than DCs (dark grey bar). (b) Enhanced ccl22 mRNA
expression level in the hippocampus of APP/PS1-CCL17E/E mice (black bar) and CCL17E/E
(dark grey) compared to APP/PS1 (white bar) and WT mice (light grey bar). Diagrams
show mean relative expression ± SEM. Data analysis: 1-way-ANOVA with Bonferroni post-
hoc; *p <0.05, **p <0.01 (APP/PS1 vs. APP/PS1-CCL17E/E), ##p <0.01 (tg vs. WT).
(a: n = 3 wells / mouse / group; b: n = 4-9 mice/group)
These data clearly show, although eGFP+ cells are absent in the CNS of APP/PS1-
CCL17E/E and CCL17E/E mice, CCL17 expression is upregulated in the CNS of APP/PS1
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mice. Further, microglia cells can express both CCR4 and its ligand CCL17. Interestingly,
CCL22 expression is upregulated in the hippocampus of CCL17-deficient mice, but not
in APP/PS1 mice.
5.1.8 Upregulation of alternative activation marker MMR and the
anti-inflammatory cytokine IL-10 in APP/PS1-CCL17E/E mice
Neuroinflammation in AD is accompanied by the expression of several cytokines such as
TNF, IL-6, and IL-1 [21]. In order to investigate the inflammatory profile in APP/PS1-
CCL17E/E mice, the expression level of pro-inflammatory cytokines and iNOS, which
are often found to be enhanced in AD [22], was analyzed in the hippocampus of aged
APP/PS1-CCL17E/E mice compared to age-matched APP/PS1. qRT-PCR analysis re-
vealed equivalent levels of inos and il-1β (Fig.5.24.a), while tnf mRNA (Fig.5.24.a) is not
significantly increased (p (tnf ) = 0.0799). However, the interleukin IL-6 is increased in
the hippocampus of aged APP/PS1-CCL17E/E animals (Fig.5.24.a). IL-6 is a pleiotropic
cytokine, with pro- and anti-inflammatory properties [140]. It is expressed by microglial
cells isolated from the CNS of AD mice [141] and is found to be elevated in AD patients
[21], although its role in AD remains unclear [142]. However, after LPS/IFNγ stimulation
of neonatal microglial cells, IL-6 protein expression is increased to an equivalent level in
the supernatant of both, WT and CCL17E/E microglia (Fig.5.24.b).
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Figure 5.24: Enhanced IL-6 expression in APP/PS1-CCL17E/E mice
(a) Analysis of pro-inflammatory cytokines revealed an upregulation of il-6 mRNA in the
hippocampus of aged APP/PS1-CCL17E/E mice (black bar) compared to APP/PS1 mice
(white bar). Diagram shows mean relative expression ± SEM. (b) Equivalent IL-6 protein
expression by LPS-stimulated WT (white bar) and CCL17E/E (black bar) neonatal microglia.
Diagram shows mean ± SEM. Data analysis: Student’s t-test, ***p < 0.001. (a: n = 6-9
mice/group; b: n = 3 wells/mouse/group); (Fig.5.24.b: Ramona Go¨hrs)
Next, the anti-inflammatory profile of aged APP/PS1-CCL17E/E mice was evaluated.
Upregulation of anti-inflammatory proteins are often related to an enhanced phagocytic
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phenotype of macrophages and microglial cells [64]. qRT-PCR analysis of markers associ-
ated with anti-inflammatory functions of macrophages such as YM-1, Arg1, TGF-β, and
IL-10 revealed equivalent levels of ym-1, tgf-β, and arg1 mRNA in the hippocampus of
APP/PS1-CCL17E/E and APP/PS1 mice (Fig.5.25.a). However, the expression of il-10
is increased in aged APP/PS1-CCL17E/E mice compared to age-matched APP/PS1 mice
(Fig.5.25.a). IL-10 is a prototypical anti-inflammatory cytokine, involved in M2 activation
of macrophages and enhanced phagocytosis [52].
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Figure 5.25: Enhanced IL-10 expression in CCL17-deficient mice
(a) Analysis of anti-inflammatory cytokines revealed an upregulation of il-10 (a) in the
hippocampus of aged APP/PS1-CCL17E/E mice (black bar) compared to APP/PS1 mice
(white bar). Diagram shows mean relative expression ± SEM. (b) Equivalent IL-10 protein
expression by LPS-stimulated WT (white bar) and CCL17E/E (black bar) BM-macrophages.
Diagram shows mean ± SEM. (c-d) Increased IL-10 mRNA (c) and protein (d) expression
by LPS-stimulated WT and CCL17E/E neonatal microglia. Diagrams show mean ± SEM.
Data analysis: Student’s t-test, *p < 0.05, ***p < 0.001. (a: n = 6-9 mice/group; b-d: n =
3 wells/mouse/group); (Fig.5.25.d: Ramona Go¨hrs)
To investigate whether macrophages or microglia are the cellular source for IL-10 ex-
pression, supernatant of BM-derived macrophages and neonatal microglial cells from WT
and CCL17E/E mice were analyzed for IL-10 production. Interestingly, BM-macrophages
of WT and CCL17E/E mice showed increased IL-10 protein secretion after LPS stimu-
lation, but differences between both strains were not detected (Fig.5.25.b). In contrast,
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neonatal microglial cells of CCL17E/E mice exhibit enhanced IL-10 mRNA and protein
expression level compared to WT cells (Fig.5.25.c, d).
The higher expression of IL-6 in the HC of APP/PS1-CCL17E/E mice indicates a higher
activation state in these mice compared to APP/PS1 mice. Further, the expression of IL-
10 indicates a shift towards a more alternative activation state in these cells, which is often
accompanied by enhanced macrophage mannose receptor (MMR) expression [63, 66]. In
order to further characterize the ICL of APP/PS1-CCL17E/E and APP/PS1 mice, the
expression of CD40 and MMR of intracerebral microglia and macrophages was assessed
by flow cytometric analysis.
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Figure 5.26: Equivalent CD40 expression by microglia
Flow cytometric analysis of surface expression of CD40 in aged APP/PS1-CCL17E/E mice
compared to APP/PS1 mice. Equivalent mean fluorescence intensity of CD40+ microglia
and macrophages in aged APP/PS1-CCL17E/E mice compared to APP/PS1 mice. Diagram
shows mean MFIgeo ± SEM. Data analysis: Student’s t-test. (n = 3-4 mice/group)
The co-stimulatory molecule CD40 is often used as a marker for activated microglial cells
in AD [128]. The analysis of the geometric mean fluoresence intensity of CD40 (MFIgeo
CD40) of macrophages and microglial cells from the CNS of APP/PS1-CCL17E/E, AP-
P/PS1, and CCCL17E/E mice revealed an increased CD40 expression by microglial cells
in APP/PS1-CCL17E/E, APP/PS1, and CCL17E/E mice, whereas macrophages showed
a lower expression of CD40. Unexpectedly, CCL17E/E mice exhibit similar MFIgeo CD40
like both AD mouse strains, although increased CD40 expression were found in the CNS of
APP/PS1-CCL17E/+ mice compared to CCL17E/+ mice. However, APP/PS1-CCL17E/E
mice present increased numbers of MMR+ macrophages and microglia isolated from the
CNS compared to APP/PS1 mice (Fig.5.27). Interestingly, the amount of MMR+ mi-
croglia was much higher (∼ 6x104) (Fig.5.27.b) than MMR+ macrophages (< 1x104)
(Fig.5.27.c).
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Figure 5.27: Enhanced MMR expression in APP/PS1-CCL17E/E mice
(a) Representative overlays of MMR histogram of microglia isolated from the CNS of aged
APP/PS1-CCL17E/E (black line) and APP/PS1(light grey solid curve) mice. (b-c) En-
hanced numbers of MMR+ microglia (b) and macrophages (c) in the CNS of aged APP/PS1-
CCL17E/E mice (black bar) compared to APP/PS1 (white bar) mice. Diagrams show mean
± SEM. Data analysis: Student’s t-test, *p <0.05. (n = 4 mice/group, 1 WT)
Altogether, these data show an altered inflammatory milieu in the CNS of APP/PS1-
CCL17E/E mice compared to APP/PS1 mice as given by enhanced IL-6 and IL-10 produc-
tion together with increased numbers of MMR+ macrophages and microglial cells indicat-
ing a shift of intracerebral microglia and macrophages towards an alternative activation
or M2 type.
5.1.9 Phagocytosis and degradation of Aβ
Alternative activation is related to a supressor phenotype of macrophages and enhanced
phagocytic ability of these cells [52, 66]. In order to investigate, whether CCL17E/E mi-
croglia or macrophages show enhanced Aβ uptake, phagocytosis assays of fluorescently-
labeled Aβ1-42 peptides by BM-derived macrophages and neonatal microglia were per-
formed. First, the internalization and degradation rate of Aβ42-DyeLight649 in vitro by
BM-derived macrophages of CCL17E/E and WT mice was measured. For this, Aβ42-
DyeLight649 peptides were added to BM-macrophages for 15 min in which the inter-
nalization process takes place. Intracellular localization of Aβ was verified by EEA-1 /
Aβ double positive cells and analysis of z-stack images of Aβ42-DyeLight649+ cells was
performed. Representative z-stack images of Aβ42-DyeLight649+ cells are depicted in
Fig.5.28.a. As shown in Fig.5.28.b, the internalization rate given by counted particles
within the cells is equivalent in both CCL17E/E and WT macrophages. Flow cytometric
analysis of Aβ42-DyeLight649+ BM-macrophages after 15 min of internalization confirmed
this showing an equivalent MFIgeo of Aβ42-DyeLight649+ BM-macrophages, although a
relatively high background for the 4◦C controls were found (Fig.5.28.c).
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Figure 5.28: Equivalent Aβ phagocytosis by CCL17E/E and WT macrophages
(a-c) Internalization assay of Aβ42-DyeLight649 by BM-derived macrophages. (a) Repre-
sentative z-stack images of BM-macrophages of WT (upper panel) and CCL17E/E (lower
panel) (scale bar = 15 µm). (b) Equivalent number of particles of internalized Aβ42-
DyeLight649 in BM-macrophages of CCL17E/E (black bar) and WT (white bar). Diagrams
show mean ± SEM. (c) Flow cytometric analysis of MFIgeo of Aβ42-DyeLight649+ BM-
derived macrophages of CCL17E/E and WT mice. Diagram shows mean ± SEM. (d-e)
Degradation assay of Aβ42-DyeLight649 by BM-derived macrophages. (d) Representative
overlays of Aβ42-DyeLight649 histograms of unstimulated (light grey solid curve) samples,
at 4◦C (dark grey solid curve), at chasing time point 0 h (black dashed line), and after 24
h of chasing (black line) are shown for WT (left) and CCL17E/E (right) BM-macrophages.
(e) Equivalent MFIgeo of Aβ42-DyeLight649+ BM-derived macrophages of CCL17E/E (black
square) and WT (open circle) mice. Curves represent mean MFIgeo ± SEM of samples
taken within 24 h at different time points after medium exchange and 4◦C sample as phago-
cytosis negative control. Data analysis: 1-way-ANOVA with Bonferroni post-hoc. (n = 3
wells/mouse/group)
It was also reported that BM-derived macrophages are able to degrade Aβ in vitro
[143]. In a second approach, Aβ42-DyeLight649 petides were incubated with the BM-
macrophages for 1 h and after medium exchange with Aβ42-DyeLight649-free medium,
chasing of the degradation of intracellular localized Aβ42-DyeLight649 within 24 h was
achieved by flow cytometry (Fig.5.28d-e). Fig.5.28.e shows degradation curves of MFIgeo
of Aβ42-DyeLight649+ BM-macrophages of several time points within 24 h. However, a
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degradation of Aβ42-DyeLight649 as given by MFIgeo, was not found. In addition, the
MFIgeo of Aβ42-DyeLight649 was equivalent in both groups for 24 h.
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Figure 5.29: Enhanced Aβ uptake by CCL17E/E microglia, reduced RAGE and enhanced
neprilysin expression levels
(a) Curves represent mean MFIgeo ± SEM of Aβ42-DyeLight649+ neonatal microglia of
CCL17E/E and WT mice within 6 h of chasing after medium exchange. Neonatal microglia
derived from CCL17E/E mice showed enhanced Aβ phagocytosis compared to WT microglia.
(b-c) Diagrams show mean relative expression ± SEM of Aβ receptors (b) and Aβ degrading
enzymes (c). Equivalent hippocampal expression ofmarco (b), ide (c), andmmp-9 mRNA (c)
in the hippocampus of aged APP/PS1-CCL17E/E and APP/PS1 mice. APP/PS1-CCL17E/E
mice exhibit reduced rage (b) and increased nep mRNA expression (c) in the hippocampus
compared to APP/PS1 mice. Data analysis: 1-way-ANOVA with Bonferroni post-hoc (a)
and Student’s t-test (b, c), *p < 0.05, **p < 0.01, ***p < 0.001. (n = 3 wells/mouse/group).
(Fig.5.29.a: Ramona Go¨hrs)
Then, the phagocytosis capacity of neonatal microglia for Aβ42-DyeLight649 was also
performed. Here, flow cytometric analysis revealed that chasing of Aβ degradation for 6 h
did not lead to a decrease of MFIgeo of Aβ42-AF649+ microglia. But, a significant higher
uptake of Aβ42-DyeLight649 by CCL17E/E microglial cells compared to WT microglia
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was found (Fig.5.29.a).
Decreased soluble Aβ levels in the CNS of aged APP/PS1-CCL17E/E mice together
with a higher Aβ uptake by CCL17E/E microglial cells raised the question, whether the
expression levels of receptors and enzymes involved in the uptake and degradation of Aβ
peptides are altered in APP/PS1-CCL17E/E mice. Major Aβ receptors are the receptor
for advanced glycation end products (RAGE) and the macrophage receptor with collage-
nous structure (MARCO), whereas important degradation enzymes are insulin-degrading
enzyme (IDE), matrix-metalloprotease-9 (MMP-9), and neprilysin (NEP) [38, 144, 145].
To adress this, qRT-PCR analysis of mRNA levels of the Aβ receptors RAGE and
MARCO, as well as the Aβ degrading enzymes IDE, MMP-9, and NEP in the hip-
pocampus of APP/PS1-CCL17E/E and APP/PS1 mice was assessed. Equivalent levels of
marco, ide, and mmp-9 mRNA were measured in the HC of aged APP/PS1-CCL17E/E
and APP/PS1 mice (Fig.5.29.b, c). However, RAGE expression level is decreased in
APP/PS1-CCL17E/E mice compared to APP/PS1, while NEP expression level is in-
creased (Fig.5.29.b, c). These data suggest a reduced Aβ-RAGE signaling in APP/PS1-
CCL17E/E mice, together with a probably enhanced Aβ degradation due to enhanced
NEP expression.
These data show that CCL17E/E deficient microglia, but not macrophages exhibit an
enhanced phagocytic capacity of Aβ in vitro, but differences in degradation were not
detected. In addition, aged APP/PS1-CCL17E/E mice present reduced RAGE, but en-
hanced NEP expression in the hippocampus, indicating an altered Aβ signaling and pro-
cessing compared to age-matched APP/PS1 mice.
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5.2 Determination of human CCL17 protein level in
plasma samples of elderly patients
CCL17 is an inducible chemokine found to be involved in several human diseases. So, it
was found at higher concentrations in the serum of patients with atopic dermatitis [112]
and in cerebrospinal fluid (CSF) and serum of multiple sclerosis (MS) patients [117, 146].
In order to investigate a possible role of CCL17 as a biomarker for Alzheimer’s disease,
CCL17 concentrations in CSF and plasma samples of AD patients should be determined.
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Figure 5.30: Analysis of human plasma CCL17 protein
Pretest for human plasma CCL17 concentration and its correlation with Aβ concentration
in cerebrospinal fluids (CSF) of elderly patients. (a) Diagram shows mean ± SEM of CCL17
protein concentration in Ctrls, MCI, and AD patients. Each dot represent one value. (b-d)
Diagrams show CSF Aβ vs. CCL17 concentration. Each dot represent one subject. Ctrls =
healthy for MCI or AD, MCI = mild cognitive impairment, AD group = Alzheimer’s disease.
Data analysis: 1-way-ANOVA with Bonferroni post-hoc (a), Pearson correlation assay, p =
0.6500, r = 0.5225 (b); p = 0.0814, r = -0.7570 (c); p = 0.9167, r = -0.03585 (d). (n = 15-18
(a); n = 3 (b), 6 (c), and 11 (d))
First, the concentration of CCL17 in CSF samples were evaluated using human CCL17
ELISA. However, the detection of CCL17 protein failed in samples of AD patients and in
healthy controls (data not shown).
Then, the analysis of plasma CCL17 levels of healthy controls, patients with mild cog-
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nitive impairment (MCI), and AD patients was performed. In healthy controls a concen-
tration of 64.48 pg/ml ± 7.201 was found, whereas in both, MCI and AD, concentrations
of 86.21 pg/ml ± 9.334 and 81.75 pg/ml ± 7.086 were measured (Fig.5.30.a). Next,
correlation assays for plasma CCL17 concentrations, found in these patients, with the re-
spective CSF Aβ1-42 levels were performed for all three groups. As shown in Fig.5.30.d,
a correlation between plasma CCL17 and CSF Aβ of AD patients could not be found.
Nevertheless, a negative correlation curve was found in MCI patients, although it is not
significant (Fig.5.30.c). The Pearson coefficient (r = -0.7570) showed a tendency to -1,
indicating a correlation for CCL17 and Aβ1-42 in these patients. To verify this, the ex-
periment for MCI patients were repeated with a higher number of samples. However,
performing the correlation assay for serum CCL17 and CSF Aβ1-42 revealed a Pearson
coefficient of r = -0.06714 and thereby not confirming the initial result (Fig.5.31).
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Figure 5.31: Human plasma CCL17 did not correlate with CSF Aβ levels in MCI patients
Correlation assay was performed for human plasma CCL17 levels with CSF Aβ levels in MCI
patients. Diagram show CSF Aβ vs. CCL17 concentration. Each dot represent one patient.
Data analysis: Correlation assay with Pearson, p = 0.5922, Pearson coefficient r = -0.06714.
(n= 66)
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In the Alzheimer’s disease international (ADI) World Alzheimer’s report it was estimated
that 2010 more than 36 million people worldwide would suffer from dementia. Around
US$604 billion were calculated by ADI for dementia care worldwide. Without a break-
through in the treatment, due to the higher life expectancy, the number of AD patients
will be doubled in twenty years [147].
Although the biochemical cause for Aβ generation is well-researched, the principal rea-
son for developing AD is totally unclear and is controversially discussed since more than
100 years. New insights by basic experimental and clinical studies using new and sophis-
ticated technicological approaches visualize a more complex view of causes for developing
AD. Genetical studies have identified more than hundred different gene mutations leading
to familial AD. Results of epidemiological studies took into account environmental stress
factors, smoking, diabetes and other risk factors. And at last, many post mortem studies
and experiments using animal models of AD featured chronic or acute inflammation at
least as a bystander if not as a cause for AD development [21, 25, 148]. The purpose of this
work was to unravel a potential role of the chemokine CCL17 in inflammatory mechanisms
occuring in AD using a CCL17-deficient APP/PS1 mouse strain, APP/PS1-CCL17E/E.
6.1 Analysis of APP/PS1-CCL17E/E mice
6.1.1 APP/PS1-CCL17E/E mice exhibit improved cognitive
performance, reduced neuronal loss and sAβ burden
First, the phenotypic behavior of APP/PS1-CCL17E/E mice in a survival paradigm and
in the Morris water maze test was assessed. For the investigation of the survival rate,
mice were weekly controlled from three to nine months of age, and fatalities were noted.
Survival analysis revealed a death rate of 15 % for APP/PS1-CCL17E/E mice within this
time, whereas 25 % of APP/PS1 mice did not survive. WT mice had a death rate of 11 %.
A previous study reported a pre-mature death rate of approximately 35 % for APP/PS1
mice before six months of age, whereas after six months of age death events were less
common [129].
Cognitive deficits of APP/PS1 mice were shown at 12 months of age [17, 130] using
Morris water maze (MWM), and at six months of age using a radial arm water maze
[129]. Here, in this study, aged APP/PS1-CCL17E/E mice had a similar escape latency
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like WT during the acquisition trial, and they spent a similar time period in the target
quadrant during probe trial. In contrast, APP/PS1 mice showed a significant impaired
cognitive behavior in both tasks, as described earlier [19]. These data clearly show a
WT-like learning and memory ability of aged APP/PS1-CCL17E/E mice in contrast to
age-matched APP/PS1 mice.
The overexpression of APP together with presenilin-1 leads to remarkable Aβ produc-
tion even in young [129] and with a strong correlation effect on cognitive functions in
aged mice [130]. Most studies showed that modulation of inflammatory responses influ-
encences cerebral amyloidosis and behavioral phenotype of AD mice in the same manner
[40, 60, 91]. Therefore, the amount of extracellular deposits, soluble Aβ oligomers and
soluble Aβ40 and Aβ42 peptides in aged APP/PS1-CCL17E/E mice was evaluated. In
addition, the amount of soluble Aβ40 and Aβ42 in the CNS and serum Aβ42 level of young
and middle-aged mice were assayed in order to investigate age-dependent alterations in
APP/PS1-CCL17E/E mice compared to APP/PS1 mice.
Interestingly, although intracerebral Aβ40 and Aβ42 levels were significant higher in
young APP/PS1-CCL17E/E mice compared to age-matched APP/PS1 controls, in the
middle-aged group differences between APP/PS1-CCL17E/E and APP/PS1 mice were
not found. Further, serum levels of Aβ42 were significant reduced in young APP/PS1-
CCL17E/E mice compared to APP/PS1 mice, equivalent serum levels were found in
middle-aged mice. However, these data indicate an age-dependent remarkable increase
of intracerebral and serum Aβ level in both, APP/PS1-CCL17E/E and APP/PS1 mice
between six and nine months of age.
The determination of Thioflavin-stained amyloid plaques in the cortex and the hip-
pocampus of aged APP/PS1-CCL17E/E and APP/PS1 mice revealed no differences nei-
ther in the precentaged area occupied by extracellular deposits nor in the mean size of
these plaques, indicating the good cognitive performance of aged APP/PS1-CCL17E/E
mice is not due to a reduced deposition of fibrillary Aβ. In a previous study it was shown,
soluble Aβ, but not amyloid plaques and insoluble Aβ, correlates with cognitive deficits
of 12-months-old APP/PS1 mice [130]. In line with this data, aged APP/PS1-CCL17E/E
mice present significant reduced soluble Aβ oligomers as shown by western blot analysis,
while middle-aged mice did not show differences in oAβ levels. Additionally, although
soluble Aβ40 levels were equivalent, soluble Aβ42 levels were reduced in the CNS of these
mice compared to APP/PS1 mice, indicating a detrimental effect on neuronal survival and
cognitive functions for Aβ42 and soluble Aβ oligomers rather than Aβ40 and extracellular
deposits. Several in vitro studies featured a higher neurotoxicity of Aβ42 monomers than
Aβ40 [9]. Except for Aβ clearance by phagocytosis and degradation, a reduction of intrac-
erebral Aβ levels can be due to several reasons. Increased insoluble Aβ deposits reduces
the soluble Aβ concentration isolated from the brain. Also, diminished plasma Aβ con-
centrations have been correlated to increase brain Aβ levels pointing to the importance
of Aβ efflux from the CNS into the periphery [43]. However, aged APP/PS1-CCL17E/E
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mice did not show enhanced serum Aβ42 levels. Also, increased plaque deposition was
not found in the CNS of aged APP/PS1-CCL17E/E mice, therefore increased Aβ uptake
and / or degradation could be one possibility. In generally, serum Aβ42 and soluble Aβ40
levels increased remarkable during aging in both strains, while soluble Aβ42 concentration
increased in APP/PS1 mice, but remained nearly constant in APP/PS1-CCL17E/E mice.
Previously it was suggested that the principal cause for cerebral dystrophy and cognitive
decline in AD patients and AD mice are extracellular deposits and Aβ fibrils [9, 150, 133].
However, based on recent data the hypothesis raised that Aβ monomers, especially Aβ42,
and Aβ oligomers are the neurotoxic compounds in the CNS rather than Aβ deposits [132,
151, 152, 153]. AD patients show successive cognitive impairments and severe neuronal
dysfunction [154, 150]. In mouse models of AD, this frank neuronal loss is not observed
[1, 19], but many strains exhibit neuritic dystrophies [15, 155], hippocampal interneuron
loss [156], or decreased neuronal activity in plaque environment [157]. The neuronal
integrity of aged APP/PS1-CCL17E/E mice were determined for NeuN+ mature neurons.
APP/PS1 displayed a marked loss of NeuN+ CA3 neurons, whereas APP/PS1-CCL17E/E
showed WT-like NeuN pattern. Some studies revealed diminished neurogenesis as shown
by BrdU+/NeuN+ [158] or DCX+ labeled neurons [159] within the hippocampal region of
these APP/PS1 mice, although a general reduction of NeuN+ neurons was not reported.
On the other hand, in these studies, mice were analyzed at an age of eight [158] and
nine [159] months, respectively, hence a progressively impaired neurogenesis with aging
potentially can be manifested by a loss of NeuN+ cells in aged APP/PS1 mice. In another
approach, the authors found a significant reduction of NeuN expression in the brain of
8-months-old APP/PS1 mice lacking the hematopoetic cell marker CD45 (PSAPP/CD45
(-/-)), but not in age-matched CD45-sufficient PSAPP littermates, indicating an increased
neurotoxic environment due to CD45 ablation [43]. Further investigation is needed to
examine, whether diminished neuronal loss in APP/PS1-CCL17E/E mice compared to
APP/PS1 mice is due to increased neurogenesis or decreased cell death. In addition,
an increased bdnf expression was found in the hippocampus of APP/PS1 mice, whereas
APP/PS1-CCL17E/E mice exhibit equivalent levels like control mice. BDNF levels were
found increased in MCI and patients with mild AD, whereas it was decreased in patients
with severe AD, suggesting a kind of compensatory mechanism in earlier stages, but
probably absent in later stages [123]. These data suggest an altered neuronal environment
in aged APP/PS1 mice in which the growth factor BDNF is upregulated in response to
an increased neuronal loss.
6.1.2 Analysis of APP/PS1-CCL17E/+ reporter mice
The overexpression of APP/Aβ in AD mice results in a massive accumulation of Aβ de-
posits and simultaneously severe neuroinflammation within the CNS. In AD patients and
in mouse models of AD several studies showed an enhanced intracerebral inflammatory
response as given by enhanced cell activation, particularly glia cells (gliosis), as well as
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expression of inflammatory mediators by these cells, e.g. inducible nitric oxide synthetase
(iNOS), TNF-α, IL-1β, or CCL2 [21, 50]. Moreover, an alteration of several periph-
eral inflammation markers, mostly enhanced serum or plasma levels of cytokines and
chemokines, are detectable in AD patients and mouse models of AD [93, 121]. In spleen
and blood of 3xTg-AD mice increased percentages of CD8+ memory T cells and CCR6+
B cells were found compared to WT mice [93]. Also, the perivascular drainage of Aβ from
the CNS to cervical lymph nodes (LNcerv) was discussed for humans [125, 126] and further
it has been shown that a DC-mediated CD4+ T cell entry into the CNS in response to Aβ
accumulation around cerebral blood vessels occur in mice [149]. Indeed, own observations
confirmed the hypothesis that peripheral circulating Aβ can be phagocytosed by CD11c+
DCs and possibly presented to T cells by upregulation of MHC II-Aβ antigen complex
[127]. Here, the influence of APP/PS1 expression on peripheral immune cells of heterozy-
gous APP/PS1-CCL17E/+ mice after disease onset was investigated. For this, flow cyto-
metric analysis of CD11b+, CD11c+ myeloid cells, or TCR+ T cells in the spleen, lymph
nodes (LN), and blood of 10-12 months old APP/PS1-CCL17E/+ was performed. In addi-
tion, cerebral immune responses were assayed by flow cytometric analysis of intracerebral
leukocytes (ICL) for CNS-resident microglia (CD45lowCD11bhigh), invading monocytes /
macrophages (CD45highCD11bhigh), and invading lymphocytes (CD45highCD11b−). The
activation status of ICL was assessed by their CD40 expression. The analysis of immune
cells in peripheral lymphoid organs, spleen, LN, and blood of APP/PS1-CCL17E/+ mice
revealed no alterations in numbers of myeloid or lymphoid cells compared to CCL17E/+
controls. These initial findings indicate that peripheral immune cells were not affected
by the overexpression of APP/Aβ in CCL17E/+ mice. However, it is possible that a
more detailed analysis of specific activation markers like CD40 and MHC II could reveal
inflammatory changes in the periphery of these mice. The date of analysis was selected
for marked plaque progression, as reported for APP/PS1 mice older than six months of
age [129]. Except of increased CD40 expression, which is always linked to microglial ac-
tivation in AD mouse models [43, 128], increased microgliosis was not detectable in these
mice, though analysis at a later date could possibly disclose an enhanced inflammatory
response in brain or periphery.
Furthermore, eGFP/CCL17 expression in spleen, LN, blood, and brain was investi-
gated using flow cytometry. It has been shown, using CCL17E/+ and CCL17E/E mice
that CCL17 is expressed by mature DCs found in lung, lymph nodes, and skin, and up-
regulated upon TLR-ligand stimulation [101]. Although normally absent in spleen [101],
eGFP+ DCs were found in spleen after NKT cell-mediated licensing to be crucial for cross
presentation [113]. However, eGFP expressing DCs in LNax,mes, LNcerv, and spleen were
equivalent for APP/PS1-CCL17E/+ and CCL17E/+ mice. The expression of eGFP in the
spleen was below 0.1 %, as it was previously reported [101]. In addition, eGFP+ cells were
not found in brain or blood in both APP/PS1-CCL17E/+ and CCL17E/+ mice. However,
previous analysis of brain slices of APP/PS1-CCL17E/+ and CCL17E/+ mice by confocal
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microscopy support these findings [127].
6.1.3 Increased microgliosis and infiltration of peripheral
macrophages in APP/PS1-CCL17E/E mice
Inflammation in AD brains of patients and mouse models are characterized by a marked
astrocytosis and microgliosis [150]. Astrocytosis is marked by increased GFAP surface
expression, while microgliosis can be measured by CD11b expression [136]. Diminished
neuronal loss was found in aged APP/PS1-CCL17E/E mice in contrast to age-matched
APP/PS1 mice. Neuronal loss is often accompanied by reactive astrocytes or microglial
cells that are either cause or defense for neuronal degeneration [160, 161]. Investigation
of GFAP+ astrocytes and CD11b+ microglial cells within the CNS of aged APP/PS1-
CCL17E/E mice revealed equivalent astrocytosis in APP/PS1-CCL17E/E and APP/PS1
mice, whereas microgliosis is enhanced in APP/PS1-CCL17E/E mice. These data indicate
an enhanced neuroinflammatory response in APP/PS1-CCL17E/E mice, without neuro-
toxic effects in these mice. Furthermore, flow cytometric analysis of CD11b+ cells in
young and middle-aged groups revealed an age-dependent increase of microgliosis in both
mouse strains, which is more pronounced in APP/PS1-CCL17E/E mice.
Increased microgliosis can be due to enhanced proliferation of CNS-resident microglial
cells or due to infiltration of peripheral monocytes that proliferate into tissue-macrophages
and can renew microglia population [162, 163]. The origin of CD11b+ cells in the CNS of
APP/PS1-CCL17E/E mice was investigated by analysis of CD45 and CD11b phenotype
of intracerebral leukocytes (ICL). Small numbers of lymphocytes, but increased numbers
of macrophages and microglial cells were found in APP/PS1-CCL17E/E mice compared to
APP/PS1 mice. Invading monocytes / macrophages in AD brains are often characterized
by the expression of CCR2 surface expression. Further, it has been shown that CCR2+
macrophages are critical in plaque clearance and cognitive performance in APP/PS1 mice
[42, 164]. The investigation of CCR2 expression within the CNS of APP/PS1-CCL17E/E
mice revealed an increase of ccr2 mRNA in young and middle-aged APP/PS1-CCL17E/E
mice compared to APP/PS1 mice, although it was not significant in aged mice. How-
ever, flow cytometric analysis of ICL revealed the highest CCR2 expression on invading
macrophages in aged mice, and it was enhanced on macrophages derived from the CNS
of APP/PS1-CCL17E/E and APP/PS1 mice compared to non-tg controls. Additionally,
total numbers of CCR2+ cells were increased in aged APP/PS1-CCL17E/E mice com-
pared to APP/PS1 mice. Furthermore, phenotypically characterization of intracerebral
Ly6ChighCCR2+ macrophages showed that they were enhanced in APP/PS1-CCL17E/E
mice compared to APP/PS1 mice, but totally absent in non-tg controls. In generally,
Ly6C+CCR2+ monocytes, derived from adult bone marrow, circulate in the peripheral
blood until they immigrate into tissue where they proliferate into DCs, macrophages,
or in case of inflamed CNS into microglial cells [71, 163]. It has also been shown in
70
6 Discussion
CCR2-deficient mice that CCR2 expression is critical for the intracerebral localization
of Ly6ChighCCR2+ monocytes in the context of EAE (experimental autoimmune en-
cephalomyelitis) development [165]. Our data support the hypothesis of beneficial effects
of CCR2+ cells in AD-like pathology and suggest a potential role of CCL17-mediated
inhibitory mechanism for CCR2+ macrophage recruitment into the brain of APP/PS1
mice.
The main ligand of CCR2 is CCL2, which has been shown to be upregulated in AD
brains and serum [75, 87]. Interestingly, overexpression of CCL2 mediates Aβ oligomer
formation and worsened cognitive perfomance in AD mice [97, 166]. Investigation of in-
tracerebral CCL2 level in APP/PS1-CCL17E/E mice revealed an age-dependent increase,
but equivalent protein level in both APP/PS1-CCL17E/E and age-matched APP/PS1
mice. These data exclude CCL2 as the sole factor for Ly6ChighCCR2+ macrophage re-
cruitment in APP/PS1-CCL17E/E mice.
6.1.4 CCL17 expression in aged APP/PS1 mice
CCL17 expression was evaluated in aged APP/PS1 and WT mice to see whether CCL17
expression is altered by APP/PS1 transgene expression. Indeed, ccl17 mRNA is in-
creased in the hippocampus of APP/PS1 mice when plaque development and cognitive
impairment is fully developed. Since the detection of eGFP+ cells in the CNS failed in
APP/PS1-CCL17E/E and CCL17E/E mice, ICL were isolated from aged APP/PS1 and
WT mice to unravel the intracerebral source for CCL17 expression. In fact, ccl17 mRNA
was found in both mouse strains, indicating intracerebral CCL17, but not eGFP expres-
sion by macrophages or microglial cells in this model. Full eGFP protein expression and
subsequent correct self-folding is needed for fluorescence emission [167]. In CCL17E/+
and CCL17E/E mice eGFP fluorescence is described for Langerhans cells and mature DCs
[101]. Although macrophages are found to express CCL17 [103, 168], up to now eGFP+
macrophages are not reported to be found in CCL17E/E mice. It is possible that full eGFP
expression is somehow disturbed at the transcription or translation level, or posttransla-
tional modifications different from that in DCs inhibit correct protein folding that eGFP
fluorescence is suppressed. A former cloning study for the mouse CX3CL1/fractalkine
gene revealed an unexpected alternative splicing variant of CCL17/TARC containing the
signal sequence of CX3CL1 and protein encoding sequence of CCL17 [169]. The authors
found that the fracTARC mRNA expression under the control of fractalkine promotor is
tissue-specific in mouse kidney and brain, while normal CCL17 is expressed in thymus,
lung, and with low amount in spleen.
The cognate receptor for CCL17 is CCR4. Several immune cells like DCs and T cells,
but also macrophages express CCR4. It has also been shown that CHME3 cells, a human
microglia cell line, and also primary human astrocytes express CCR4 [138]. Here, it was
found that neonatal mouse microglia express ccr4 mRNA upon LPS stimulation, although
the expression level is lower than that of LPS stimulated DCs. However, a potential
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auto- or paracrine signaling mechanism of microglial CCL17-CCR4 pathway is possibly
involved in AD-linked neuroinflammation. On the other hand, a former study reported a
Ca2+ increase in CCR4+ hippocampal neurons stimulated with CCL17 [139], indicating a
direct signaling between microglia and neurons via the CCL17-CCR4 axis. The principal
function of CCL17 is the chemotactic recruitment of cells expressing its cognate receptor
CCR4. Previous data of our group showed that Ly6C+CCR2+ monocytes express CCR4
[115]. Since increased recruitment of peripheral macrophages into the CNS is apparent in
APP/PS1-CCL17E/E mice, the question raised whether CCL22, the other CCR4 ligand
is altered in APP/PS1-CCL17E/E mice. Expression analysis revealed that ccl22 mRNA
is upregulated in the hippocampus of both CCL17E/E and APP/PS1-CCL17E/E mice
compared to WT and APP/PS1. Interestingly, in contrast to CCL17, CCL22 is not altered
by APP/Aβ overexpression. A potential synergistic working mechanism for CCL22 and
CCL2 in the recruitment of Ly6ChighCCR2+CCR4+ monocytes into the CNS of aged
APP/PS1-CCL17E/E is possible.
6.1.5 M2 shift and enhanced phagocytosis ability by CCL17-deficient
microglial cells
The increased microgliosis and infiltration of peripheral macrophages suggest an alteration
in the inflammatory milieu indicated by an altered expression of inflammatory mediators.
While TNF, iNOS, IL-1β, YM-1, Arg1, and TGF-β present an equivalent expression
level, increased il-6 and il-10 mRNA levels were found in the hippocampus of APP/PS1-
CCL17E/E mice compared to APP/PS1 controls. IL-6 mediates, depending on the soluble
or membrane-bound form of IL-6 receptor, pro- or anti-inflammatory signaling [170]. In-
deed, in a previous study it has been shown that viral-mediated IL-6 overexpression in
a mouse model of AD decreases plaque deposition, which is accompanied by enhanced
astrocytosis and microgliosis [142]. In vitro studies of LPS-stimulated astrocytes showed
neurotrophic functions of IL-6 by increasing the survival of dopaminergic neurons in a
dose-dependent manner [160]. IL-10 is a prototypic anti-inflammatory cytokine blocking
pro-inflammatory cytokine production and downregulating MHC II and co-stimulatory
molecules on DCs and macrophages [171]. IL-10 can be expressed in the CNS by mi-
croglia, astrocytes, and oligodendrocytes and supports neuronal survival indirectly by the
suppression of a pro-inflammatory phenotype of CNS-derived glia cells or directly on neu-
rons via IL-10R signaling [172, 173]. Overexpression of IL-10 in APP/PS1 mice improved
cognitive function and increased neurogenesis while reducing astrocytosis and microgliosis
in APP/PS1 mice [159]. In addition, stimulation of macrophages or microglia with IL-10
in vitro shifts these cells towards an alternative activated phenotype. Furthermore, flow
cytometric analysis of surface expression of CD40, a co-stimulatory molecule expressed
by reactive microglia, and MMR, which is expressed by M2 macrophages revealed that
CD40 is equivalently expressed by microglia of APP/PS1-CCL17E/E, APP/PS1 mice, and
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CCL17E/E, but nearly absent on invading macrophages. However, increased numbers of
MMR+ microglia and macrophages are found in APP/PS1-CCL17E/E mice, indicating
that these cells possess a more alternatively activated phenotype in the CNS of aged
APP/PS1-CCL17E/E mice.
Alternative activation of macrophages or microglial cells may lead to enhanced phago-
cytosis of Aβ peptides [50, 63, 174]. The phagocytosis ability of BM-dervied macrophages
and neonatal microglia was assayed by using fluorescence-labeled Aβ1-42 peptide. Inter-
nalization and degradation assays revealed equivalent phagocytosis of Aβ peptides by
CCL17E/E and WT macrophages. Intracellular Aβ peptides retain in macrophages for
several hours, equivalent degradation probably takes place after 24 h of chasing. In con-
trast to the data found here in this model, it was reported that macrophages degrade
Aβ within 24 h of incubation [175], Other authors also showed an effective reduction of
intracellular Aβ by macrophages only after 64 h of incubation [143], hence a longer chas-
ing period for Aβ degradation by CCL17E/E macrophages and microglia is required to
assay the complete degradation process. However, neonatal CCL17E/E microglia exhibit
enhanced Aβ uptake compared to WT mice, although Aβ degradation was not seen in
the first 6 hours after medium exchange similar to BM-derived macrophages. Although
microglia potentially degrade Aβ peptides when cultured on AD brain sections [44], other
data indicate that microglia degrade internalized Aβ only after M-CSF stimulation lead-
ing to the acidification of lysosomes [48]. Nevertheless, these data support a potential Aβ
clearance mechanism by CNS-resident microglial cells leading to the reduced soluble Aβ
levels found in the CNS of aged APP/PS1-CCL17E/E mice.
The expression of MARCO and RAGE was examined by qRT-PCR, and an equivalent
expression level of marco mRNA, but reduced expression of rage mRNA was detected in
the hippocampus of APP/PS1-CCL17E/E mice. RAGE binds soluble Aβ monomers or
oligomers and mediates on the one hand the transport of Aβ peptides from the periphery
into the CNS leading to Aβ accumulation [133]. On the other hand Aβ-induced RAGE
signaling results in several activation incidents. In APP/PS1 mice activation of RAGE
via Aβ induces overactivation of autophagy, hence promoting neurodegeneration by the
accumulation of autophagolysosomes [176]. Further, it has been shown that microglial
RAGE-signaling in mouse models of AD increases the production of TNF-α and IL-1β,
Aβ accumulation, and cognitive deficits [177]. Interestingly, it was found that RAGE
was decreased in the hippocampus of 18-month-old APP/PS1 mice [178]. However, this
is accompanied by a switch of alternatively activated microglia in young to classically
activated microglia in old mice. In contrast to these data, in the CNS of aged APP/PS1-
CCL17E/E mice decreased rage expression is accompanied by a M2 shift of microglial cells,
indicating a potential beneficial effect by a reduced RAGE signaling in this model. The
expression analysis of Aβ-degrading enzymes revealed equivalent levels of ide and mmp-
9. However, nep mRNA level is enhanced in APP/PS1-CCL17E/E mice compared to
APP/PS1 mice, indicating a potentially enhanced neprilysin protein expression leading
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to enhanced Aβ monomer and oligomer degradation. These data are in line with the
reduced soluble Aβ concentration found in APP/PS1-CCL17E/E mice. However, the
enzymatic activity of MMP-9, IDE, and NEP proteins needs further investigation, to
determine whether their Aβ degradation ability is altered in APP/PS1-CCL17E/E mice.
Our data indicate enhanced Aβ clearance in the CNS of APP/PS1-CCL17E/E by mi-
croglia, but not macrophages. Although increased infiltration of peripheral macrophages
into the CNS of APP/PS1-CCL17E/E mice were found, which has been shown to be more
effective in Aβ clearance [40, 48], phagocytosis assay with BM-derived macrophages failed
to show enhanced uptake and degradation. These data suggest a possibly synergistic ef-
fect of increased Aβ uptake by CNS-resident microglia together with enhanced numbers
of infiltrating macrophages leading to decreased soluble Aβ in the CNS of APP/PS1-
CCL17E/E mice. Another explanation could be that in vivo CNS-invading macrophages
potentially adopt an CNS-related microglial phenotype differently from that of in vitro
cultured and matured BM-derived macrophages.
6.2 Determination of human CCL17 protein level in
plasma of elderly patients
The chemokine CCL17 suggest a functional role in the progression of Alzheimer’s disease
as shown by enhanced expression in the hippocampus of aged APP/PS1 mice compared
to age-matched WT mice. And breeding APP/PS1 mice with CCL17E/E-deficient mice
revealed beneficial effects on learning and memory performance in MWM, neuronal loss,
and soluble Aβ burden due to CCL17 deficiency. To investigate, whether CCL17 is altered
in the CSF of AD patients and patients with mild cognitive impairment (MCI), CCL17
concentration was determined in pre-test samples of healthy, MCI, and AD subjects by
human CCL17 ELISA. However, CCL17 protein content was indetectable in these samples.
Although some studies found CCL17 protein concentrations at 10-15 pg/ml in the CSF
of relapsing neuromyelitis optica (RNMO) and MS patients measured by ELISA, others
also reported that CCL17 concentration is under the detection limit of the used ELISA
[179, 180, 146]. Since the minimum detectable concentration of CCL17 using comercial
avaible ELISA is around 7 pg/ml, another detection system, for example a fluorescence-
based protein-assay (with higher detection sensitivity) or analysis by mass spectrometry,
seems to be reasonable.
Nevertheless, others showed measurable levels of CCL17 in plasma samples of MS pa-
tients using comercial available ELISA [146]. Plasma proteins as biomarkers for AD are
highly desirable because of the easier and less painful way of sample-taking for the pa-
tients. CCL17 protein concentration was analyzed in plasma samples of all three groups.
Although good detectable levels of plasma CCL17 were found, all groups present equiva-
lent CCL17 content. Pre-test correlation assays for plasma CCL17 and CSF-Aβ42 found
indications for a correlation in MCI patients. Since the test group size of this pre-test was
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relatively low, the experiment was repeated with increased group size. However, there
was no correlation found between plasma CCL17 and CSF-Aβ42 concentrations. Since
the date of sample-taking ranges from 2000 to 2010, it is possible that some samples
had lowered CCL17 concentrations due to degradation processes, although samples were
stored at -80◦C. Nevertheless, further investigation of CCL17 as a possible biomarker for
Alzheimer’s disease might be promising.
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The purpose of this project was to investigate the potential effect of CCL17 in the neu-
roinflammatory response occuring in AD. For this, a CCL17E/E-deficient mouse model for
AD was used (APP/PS1-CCL17E/E). APP/PS1-CCL17E/E showed a WT-like learning
and memory performance in Morris water maze together with reduced levels of soluble Aβ
oligomers and Aβ42 peptides at 12-14 months of age, when cognitive deficits and plaque
deposition are fully developed in normal APP/PS1 [17, 130]. Surprisingly, APP/PS1-
CCL17E/E mice exhibit equivalent reactive GFAP+ astrocytes, but enhanced microglio-
sis. CD11b+ microglial cells derive from CNS-resident microglia and from peripheral
Ly6ChighCCR2+ monocytes / macrophages infiltrating the CNS of APP/PS1-CCL17E/E
mice. Increased CCL22, but not CCL2 expression was found in the hippocampus of
APP/PS1-CCL17E/E mice, suggesting a potential convergent recruitment mechanism of
Ly6ChighCCR2+CCR4+ monocytes. For the first time it could be demonstrated that
microglia isolated from the CNS of APP/PS1 mice express CCL17. The cognate recep-
tor CCR4 is expressed by neonatal microglia upon LPS stimulation, indicating a para-
or autocrine signaling. As indicated by increased hippocampal IL-6 and IL-10 expres-
sion, APP/PS1-CCL17E/E mice showed an altered inflammatory reponse in the CNS.
Furthermore, CCL17E/Emicroglia, but not macrophages, show enhanced expression of
IL-10 in vitro and MMR expression in vivo. Phagocytosis assay of fluorescence-labeled
Aβ1−42 peptide revealed an increased uptake by neonatal microglia, but not by BM-
derived macrophages of CCL17E/E mice. Analysis of hippocampal expression levels of
Aβ receptors and degrading enzymes revealed an increase of neprilysin, accompanied by
a decrease of RAGE supporting the hypothesis of enhanced Aβ degradation within the
CNS of APP/PS1-CCL17E/E mice, but reduced detrimental signaling. Fig.7.1 summa-
rizes the potential mechanisms and effects of CCL17 deficiency in APP/PS1 mice. The
underlying mechanism possibly involves the recruitment of peripheral macrophages into
the CNS, accompanied by a more anti-inflammatory and neurotrophic milieu. Further-
more, enhanced Aβ clearance is indicated by increased uptake and enhanced neprilysin
expression level.
These data clearly demonstrate a crucial role of CCL17 in the development of AD-like
phenotypes in a double transgenic APP/PS1 mouse model. However, the exact working
mechanism of the chemokine CCL17 in AD needs further investigation.
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Figure 7.1: CCL17 deficiency in APP/PS1 mice
CCL17 deficiency results in reduced cognitive impairment, neuronal loss, and soluble Aβ
burden. Microgliosis is enhanced due to increased CNS-resident microglial cells, which ex-
hibit increased M2 phenotype and increased uptake of Aβ peptides in vitro, and due to in-
creased infiltration of beneficial peripheral Ly6ChighCCR2+CCR4+ monocytes. IL-6 can act
as a potential neurotrophic factor. Increased CCL22 in concert with CCL2 possibly recruits
Ly6ChighCCR2+CCR4+ monocytes, which may contribute to renew of microglial population.
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